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Introduction 
 
 
 Hematopoiesis mostly occurs in bone marrow. Pluripotent stem cells give rise to 
progenitor cells of both the lymphoid lineage and the myeloid lineage. A lymphoid 
progenitor cell can develop into a B or T lymphocyte. Leukemia is characterised by 
uncontrolled proliferation of hematopoietic cells, which may result in an excess of 
malignant cells in blood.  
 
 
1.1 Acute lymphoblastic leukemia 
 
 Acute lymphoblastic leukemia (ALL) is characterized by an uncontrolled 
proliferation of lymphoblasts, and is the most frequent form of childhood cancers,1 
with approximately 100 to 120 new cases diagnosed in the Netherlands yearly. 
Treatment has made great progress during the last three decades. Nowadays 
disease free survival (DFS) in the total group of ALL patients, 5 years after diagnosis, 
is approximately 70% in the Netherlands, whereas it was 4% in the early seventies.2-5 
Currently, the tendency is to perform risk-adapted treatment to further increase 
survival and minimize (long term) toxicity. This could, among other methods, be 
achieved by using the knowledge of drug metabolism in patients. In this thesis, 
various aspects of the metabolism of the drug 6-mercaptopurine (6MP) in pediatric 
patients with ALL are described. 
 
 
1.2 6-Mercaptopurine 
  
 It has been shown that DFS in children with ALL is positively related to the 
formation of active 6MP metabolites after treatment with 6MP.6 In the conversion of 
6MP to these active metabolites, several enzymes play a role. This thesis describes 
the course of three key enzymes involved in 6MP metabolism during ALL treatment. 
 
The drug 6MP is frequently used in most ALL regimens, especially during the 
maintenance phase of treatment. Although five decades have past since Elion and 
colleagues synthesized 6MP,7 and Burchenal and colleagues described the 
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antileukemic properties of this compound,8 its metabolism and working mechanism 
still are not completely elucidated. The studies described in this thesis focus on 6MP 
metabolism to obtain knowledge to further improve the maintenance treatment in 
children with ALL.  
 
 
1.2.1 Metabolism of 6MP 
 
 6MP is a hypoxanthine analogue, and is activated by endogenous purine enzymes 
(see figure on the fold-out page at the back of this thesis). The conversion of 6MP to 
thioinosine monophosphate (thio-IMP) is catalyzed by hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT), and needs phosphoribosyl pyrophosphate 
(PRPP) as a cosubstrate. Thio-IMP can be converted by the rate-limiting enzyme 
inosine monophosphate dehydrogenase (IMPDH) and guanosine monophosphate 
synthetase to the cytotoxic thioguanine nucleotides (TGNs), which are incorporated 
into DNA and RNA.9 These incorporated thionucleotides result in the induction of 
single strand breaks, cross links in the DNA-protein complex, interstrand cross links 
and sister chromatid exchanges, in short: DNA damage.10-16 This may lead to growth 
arrest of the cells in the G2 and M phase, especially in quickly dividing malignant 
cells.17,18 
 
 A second cytotoxic pathway in 6MP metabolism is the methylation of thio-IMP 
to methylthio-IMP by thiopurine-S-methyltransferase (TPMT), which is a cytosolic 
enzyme catalysing S-methylation of aromatic and heterocyclic sulphhydryl 
compounds. Methylthio-IMP has been shown to inhibit phosphoribosyl 
pyrophosphate amidotransferase, the first enzyme in the purine de novo synthesis 
(PDNS), thereby inhibiting cell growth.19-22 The PDNS is more active in lymphoblasts 
as compared to lymphocytes, so inhibitors of this pathway may be agents in ALL 
treatment.23  
 
 Methylation of 6MP is part of its catabolic pathway. Another enzyme in the 
catabolic pathway is xanthine dehydrogenase (XDH). XDH activity is negligible in 
normal leucocytes and erythrocytes.24 5’-Nucleotidase (5’NT) degrades the 
mononucleotides thio-IMP, thio-GMP and methylthio-IMP to their corresponding 
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nucleosides. By the action of the reversibly-acting enzyme purine nucleoside 
phosphorylase (PNP), breakdown may proceed from the thionucleosides 6MP-
riboside (6MPR) and thioguanosine to form the corresponding thiopurine bases 6MP 
and thioguanine.  
 
 
1.2.2 Relevance of enzymes involved in 6MP metabolism 
 
 
1.2.2.1 IMPDH 
 
 
 IMPDH, the rate-limiting enzyme in the conversion of thio-IMP to thio-GMP, has 
been studied earlier in relation to leukemia.25,26 Two isoforms of IMPDH have been 
described: type I and type II. Type I is the sole isoform in resting lymphocytes, 
whereas type II is upregulated in neoplasms.27-33 Lymphocytic IMPDH activity was 
higher at diagnosis of leukemia, apparently due to the presence of lymphoblasts. To 
our knowledge, studies investigating the course of IMPDH activity during treatment 
with 6MP or other thiopurines have not been reported. Changes in IMPDH activity 
during thiopurine treatment may influence the drug’s effect: e.g., an increase of 
IMPDH activity may lead to a more effective treatment. In this thesis, the course of 
IMPDH activity is monitored during ALL treatment. 
 
 
1.2.2.2 5’NT 
 
 There are several 5’nucleotidases (5’NTs), which constitute a family: i.e. 
cytoplasmic 5’NTs, mitochondrial 5’NT and membrane-bound 5’NT.34-44 Cytosolic 
5’NTs regulate cellular nucleotide and nucleoside levels and degrade 
monophosphorylated thionucleotides to the corresponding thionucleosides.  
Extracellular, membrane-bound, 5’NT regulates the extracellular nucleotide pool. It 
has been reported that a high activity of membrane-bound 5’NT at diagnosis is 
associated with a worse prognosis in ALL,45,46 due to a higher degradation of 
thionucleotides. Total purine 5’NT also appeared to have clinical relevance, since 
5’NT deficiency has been shown to cause hematological toxicity in thiopurine-treated 
rheumatological patients,47 due to an accumulation of thionucleotides. So, purine 
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5’NT activity could be relevant for optimisation of the 6MP dose. Therefore, the 
course of overall purine 5’NT activity from diagnosis throughout ALL treatment is 
investigated in this thesis.  
 
 
1.2.2.3 TPMT 
 
 IMPDH and 5’NT are key enzymes in purine metabolism. The physiological 
function of TPMT has not been established. The role of TPMT in 6MP efficacy is 
equivocal. Methylation of 6MP and most of its metabolites seems to have a 
detoxifying effect in vivo, because inactive metabolites are formed. However, TPMT 
has an activating role when thio-IMP is converted into methylthio-IMP.  
 
Several studies describe dose-limiting hematological toxicity in TPMT-deficient 
patients who were treated with thiopurines. Thiopurines may have to be temporarily 
withdrawn and/or the given dose may be adjusted in these patients to prevent this 
toxicity.48-51 Full thiopurine treatment of a patient with TPMT deficiency resulted in 
more frequent hospitalization, more platelet transfusions and reduction of planned 
doses of chemotherapy.52 Additionally, it has been shown that patients with a low 
TPMT activity might be more susceptible to long-term effects of 6MP chemotherapy, 
e.g., an increased cancer risk was shown in ALL patients with a low TPMT activity 
after they had been treated with 6MP and other cytotoxic drugs or when cytostatics 
were given in combination with cranial radiotherapy.53,54 On the other hand, treatment 
failure occurs more often if patients have a high TPMT activity and/or a low TGN 
concentration.55-59 
 
Hematological side effects not only occurred in patients with a homozygous 
mutant genotype, but also at heterozygosity or even in wild-type patients.52,60-64 Other 
factors could also be relevant, e.g., the activity of other key enzymes in 6MP 
metabolism, as discussed in preceding sections of this introduction. Furthermore, 
there are in vitro data showing that there is also evidence for a positive relationship 
between TPMT activity and 6MP cytotoxicity. Van Loon & Weinshilboum showed that 
mitogen-stimulated human peripheral blood lymphocytes with a high TPMT activity 
were more sensitive to 6MP-induced growth inhibition, as compared to the 
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lymphocytes of individuals with a lower TPMT activity.65 The importance of thio-IMP 
methylation for the antiproliferative effects of 6MP was also shown in studies in 
TPMT-upregulated human T-lymphoblasts or TPMT-transfected embryonic kidney 
cells, because the cells with a high TPMT activity were more sensitive to 6MP.66,67 
There is also in vivo evidence of the importance of methylation of 6MP or its 
metabolites, since a higher susceptibility to hepatotoxicity was shown in thiopurine-
treated individuals with a normal TPMT activity and a high concentration of 
methylated metabolites.67,68 In addition, a favorable outcome was shown in patients 
with ALL experiencing hepatotoxicity during 6MP treatment.69  
 
 Some studies reported on TPMT activities in patients with ALL, at diagnosis, 
during and after maintenance treatment.70,71 In these studies, TPMT activity was 
significantly increased during maintenance treatment with 6MP and methotrexate 
(MTX), compared to TPMT activities at diagnosis and after cessation of maintenance 
treatment. TPMT activity decreased to control values after cessation of leukemia 
treatment with 6MP and MTX.6,70,71 In these studies, TPMT measurements during 
treatment were only performed when 6MP was administered. In this thesis, however, 
the course of TPMT activity during the whole ALL treatment is addressed, so not only 
during 6MP treatment. This gives additional information on the behaviour of the 
TPMT enzyme, leading to an increased knowledge concerning the role of TPMT in 
6MP metabolism, which could be used for a risk-adapted treatment. 
 
 
1.3 Aim of this thesis 
 
 This thesis aims to get more insight into 6MP metabolism in pediatric ALL. The 
main question addressed is:  
 
What is the course of the purine key enzymes 5’NT and IMPDH, and TPMT 
during treatment of children with ALL? 
 
 
Therefore, we monitored the activities of TPMT (chapter 4) and IMPDH (chapter 5) 
in children from diagnosis to one year after cessation of ALL treatment. The role of 
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5’NT in thiopurine metabolism is studied in more detail in chapter 6. The main 
findings described in this thesis are discussed in chapter 7. In this chapter, also 
future perspectives are given.  
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Abstract 
 
Monitoring 6-thiopurine S-methyltransferase (TPMT; EC 2.1.1.67) activity is 
especially important when patients are treated with 6-thiopurine drugs, since severe 
bone marrow toxicity may be induced if patients have deficient TPMT activity.  
We have developed a method based on high-performance liquid chromatography 
(HPLC) for the measurement of TPMT activity in various cell types: erythrocytes 
(RBC), human peripheral blood mononuclear cells (pMNC) and human malignant 
lymphoblasts (Molt-F4). The enzymatic activity is measured by the amount of 6-
methylmercaptopurine (6MeMP) formed, using 6-mercaptopurine (6MP) as substrate 
and S-adenosylmethionine (SAM) as cosubstrate.  
The Km values calculated for 6MP are 0.54 (RBC), 0.85 (pMNC) and 0.65 mM (Molt-
F4 cells). The Km values for SAM are 11.9 (RBC), 16.4 (pMNC) and 6.65 µM (Molt-F4 
cells). The assay variation was 8.2 - 17 %. TPMT activity was determined in a control 
group of 103 children and young adults (44 female, 59 male). The values observed 
were (mean ± standard deviation): female children and young adults, 15.1 ± 4.8 
pmol/107 cells per hr (n=44): male children and young adults, 15.8 ± 6.4 pmol/107 
cells per hr (n=59). No gender or age differences were found. 
The HPLC-based method enables the rapid screening of TPMT activities in large 
groups of patients treated with 6-thiopurines. 
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Introduction 
 
TPMT is an important enzyme in the metabolism of 6MP and azathioprine. 
6MP is a well known drug in the treatment of acute lymphoblastic leukemia (ALL).1 
Azathioprine is widely used as an immunosuppressive agent in rheumatological 
diseases, a variety of dermatological conditions, gastroenterology, neurology, 
Behçet’s disease and during follow-up treatment of renal transplantation and other 
tissue transplants.2-6 It is converted rapidly to 6MP in vivo and may be further 
converted by various pathways: it may be metabolized to 6-thioguanine nucleotides, 
a multi-step conversion initially catalysed by hypoxanthine-guanine 
phosphoribosyltransferase; it may be converted to 6-mercapto-8-hydroxypurine and 
thiouric acid by xanthine dehydrogenase or it may be 6-S-methylated to 6-
methylmercaptopurine (6MeMP) by TPMT.7 It is known that a marked variation exists 
in TPMT activity between individuals, controlled by an allelic polymorphism for either 
normal or deficient enzyme activity.8-10 The frequency distribution of TPMT activity is 
trimodal; in a normal population 84-89% is homozygous for the wildtype (TPMT*1/*1) 
allele whereas only 0.3% has mutations in both alleles and the remaining 6-11% of 
the population is heterozygous with one allele affected. The genetic polymorphism of 
TPMT becomes significant when patients are treated with 6MP or azathioprine. 
Patients with completely deficient TPMT activity, and also some heterozygous 
individuals, are at risk of profound myelotoxicity when treated with azathioprine or 
6MP.2,11-14 It has recently been reported that in rheumatoid arthritis, inherited 
intermediate TPMT activity seems to be predictive for the development of severe side 
effects from azathioprine.15 On the other hand, individuals homozygous for 
TPMT*1/*1 may be less effectively treated with standard dosages of oral 6MP or 
azathioprine.14,16,17 In addition, it has also been shown that TPMT activities in RBC 
may be induced during maintenance treatment of ALL with 6MP.18 
In order to measure TPMT activity for diagnostic and research purposes, it 
was necessary to develop a quick and reliable method. The results obtained using 
this method were compared with the results obtained using other methods and 
reference values were determined.  
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Materials and methods 
 
Reference material 
 
To establish reference values, heparinized blood was taken from control 
patients in our pediatric department, following written informed consent by the 
patients and/or their parents/guardians.  
 
 
Chemicals 
 
6MP, 6MeMP, SAM, dithiothreitol and allopurinol were purchased from Sigma 
(St. Louis MO, USA). All other chemicals were obtained from Merck (Darmstadt, 
Germany). The water used for all buffers was purified in a Milli-Q System (Millipore, 
Bedford MA, USA). 
 
 
Cell isolation and cell preparation  
 
RBC were isolated from 5 ml of heparinized blood, suspended in phosphate 
buffered 0.9% saline (PBS, total volume 5 ml) and centrifuged at room temperature 
for 10 min at 160 g. The RBC were resuspended in 5 ml of PBS and centrifuged 10 
min at 160 g. This procedure was repeated once more, but with centrifugation at 640 
g. The supernatant was removed, 2 ml of PBS were added to the RBC pellet, the 
cells were suspended again and counted with a Coulter Counter (model Z1, Coulter 
Electronics, Luton, UK). The RBC were lysed by addition of 2 ml of RBC suspension 
to 6 ml of ice cold water in a 15-ml tube. After stirring well, the lysate was kept on ice 
for 10 min and then divided into 2-ml aliquots. The aliquots were centrifuged at 4oC 
for 10 min at 14 000 g. From each aliquot 1 ml of the supernatant was collected in an 
Eppendorf tube and stored at –80oC until further measurement.  
 
To compare activity based on number of cells with activity based on protein, 
the amount of lysed RBC was measured and the protein content of the lysate was 
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measured by Lowry’s method. The analyses were performed on samples from a 
subset of 10 patients with ALL and from 10 control patients.  
 
For the preparation of pMNC, heparinized venous blood (5 ml) was 
immediately processed by Ficoll-Isopaque isolation according to the procedure 
described earlier.19 An equal volume of PBS was added to the heparinized blood and 
8 ml of this suspension were carefully layered on top of a density gradient, consisting 
of 4 ml of Lymphoprep (density 1.077 g/ml; Nycomed) and centrifuged (Hettich 
Universal 30 RF, Hettich Zentrifugen, Tuttlingen, Germany) at room temperature for 
20 min at 1,000 g. pMNC were collected from the interphase, washed with an equal 
volume of PBS and centrifuged at room temperature for 5 min at 825 g. 
Contaminating RBC were eliminated by suspending the cell pellet in 10 ml of RBC 
shock solution, consisting of 70 mM Tris-HCl and 155 mM NH4Cl (v/v 1:9, pH 7.2-
7.4).  The suspension was incubated in a waterbath for 15 min at 37oC and then 
centrifuged at room temperature for 5 min at 825 g. The cell pellet was resuspended 
and washed twice in approximately 15 ml of PBS and centrifuged after each washing 
step at 20oC for 5 min at 825 g. The cell pellet was then suspended in 1.25 ml of a 
solution containing PBS plus 4% bovine serum albumin and stored on ice until cell 
counts were performed. Numbers of white blood cells were determined with a Coulter 
counter. Cell viability was monitored by staining with trypan blue (normally 95±3%).  
 
Lymphoblasts of the Molt-F4 T-ALL cell line were cultured according to the 
previously described procedure,20 with some modifications. The cells were cultured in 
RPMI 1640 medium with Glutamax-1 (Gibco) supplemented with 10% fetal calf 
serum, 2 mM sodium pyruvate (BDH Chemicals Ltd, UK) and gentamicin (50 µg/ml; 
Invitrogen, UK). 
 
The numbers of pMNC or Molt-F4 cells were then counted and corrected for 
cell viability. The required numbers of cells were collected in Eppendorf tubes (the 
exact number was noted). The cells were freeze-dried and stored at –80oC until 
enzyme incubations were performed.  
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Enzyme incubations  
 
The following solutions were prepared: 
Solution A: 150 mM potassium phosphate buffer, pH 7.5 
Solution B: buffer containing 750 µM SAM + 3.75 mM DL-dithiothreitol 
  + 300 µM allopurinol + 150 mM potassium phosphate, pH 7.5 
Solution C: buffer containing 100 µM SAM + 500 µM dithiothreitol 
  + 40 µM allopurinol + 150 mM potassium phosphate, pH 7.5 
Solution D: 67 mM 6MP in dimethyl sulphoxide (DMSO) 
Solution E: 225 mM 6MP in DMSO 
The enzyme assays from patients` samples were performed in triplicate at least. 
 
Enzyme incubations of RBC, pMNC and Molt-F4 cells were performed 
according to the following procedures. 
 
Erythrocytes 
The incubation was initiated by adding 100 µl of RBC lysate to 125 µl of 
incubation mixture (consisting of 102 µl of solution A + 15 µl of solution B + 8 µl of 
solution D). An enzyme blank was performed using 100 µl of PBS instead of 100 µl of 
RBC lysate. A substrate blank was included using 8 µl of DMSO instead of 8 µl of 
solution D. After 2 hrs of incubation at 37oC, the reaction was stopped with 11.3 µl of 
ice cold 8 M HClO4. The samples and the blanks were immediately kept on ice for 10 
min and then centrifuged for 5 min at 14 000 g. The supernatants were neutralized 
with 4 M K2HPO4 and kept on ice for another 10 min. The neutralized samples and 
neutralized blanks were also centrifuged for 5 min at 14 000 g. The supernatants of 
this second centrifugation step were now ready for HPLC analysis. 
 
Peripheral blood mononuclear cells and Molt-F4 cells 
The enzyme reaction was initiated by addition of incubation mixture (consisting 
of 50 µl of solution A + 50 µl of solution C + 1 µl of solution E) to the freeze-dried cell 
pellet. The enzyme blank was performed without the freeze-dried cells, and the 
substrate blank (no substrate) contained 1 µl of DMSO instead of solution E. After 2 
hrs of incubation at 37oC, 5 µl of ice cold 8 M HClO4 were added to stop the reaction. 
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The samples and blanks were kept immediately on ice for 10 min and then 
centrifuged for 5 min at 14 000 g. After centrifugation, the supernatants were 
neutralized with 4 M K2HPO4 and kept on ice for another 10 min. The neutralized 
samples and blanks were also centrifuged for 5 min at 14 000 g. The supernatants of 
this second centrifugation step were now ready for HPLC analysis. 
 
 
High-performance liquid chromatography analysis 
 
The analysis was performed, using an automated HPLC system consisting of 
an autosampler (100-µl sample loop), a gradient HPLC pump, a controller, a 
continuous mobile phase degasser and a diode array detector (all from Waters, 
Millipore Corporation). 6MP and 6MeMP were separated on an Alltima reversed-
phase C18 rocket HPLC column (56x7 mm ID, particle size 3 µm) (Alltech, Deerfield 
IL, USA). The samples were eluted from the HPLC column with a 50 mM KH2PO4 
buffer, containing 25% methanol. The operation pressure is ± 90 bar and the flow-
rate was set at 2.50 ml/min. Automatic data capture and data processing were 
performed using Water-Millennium-NT32 software (Waters, Millipore Corporation). 
The enzyme activity was calculated from the amount of 6MeMP formed during the 
incubation.  
 
 
Results 
 
 
High-performance liquid chromatography analysis and 
reproducibility of the method 
 
Chromatograms of the several cell types, obtained at a wavelength of 290 nm, 
showed well-separated peaks of 6MeMP and 6MP. In Figure 1, examples of 
chromatographic separation are given for TPMT assays in RBC and pMNC. The 
retention times for 6MP and 6MeMP were 1.0 ± 0.2 min and 4.0 ± 0.5 min, 
respectively. The amounts of 6MeMP formed were calculated from peak areas of the 
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chromatograms at 290 nm. No 6MeMP was observed in the enzyme and substrate 
blanks.  
 
 
 
Figure 1. High-performance liquid chromatography (HPLC). (a) Substrate blank from an erythrocyte 
(RBC) sample; (b) thiopurine-S-methyltransferase (TPMT) activity in an RBC sample; (c) substrate 
blank from a sample of peripheral blood mononuclear cells (pMNC); (d) TPMT activity in a pMNC 
sample. AU = absorbance units; 6MP = 6-mercaptopurine; 6MeMP = 6-methylmercaptopurine. 
 
 
Calibration curves of known amounts of 6MeMP standards, dissolved in the 
initial elution buffer in concentrations ranging from 0.1 to 4.0 µM (10 – 400 pmol per 
injection), showed a good linearity between concentration (C) of 6MeMP and peak 
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area at 290 nm (C6MeMP = 1.5556 x 10-5 x area + 0.068 µM), with a variance 
coefficient of 0.9985 and mean recovery±SD of 99.7±0.3%. The detection limit was 5 
pmol per 100-µl injection.  The recoveries of standards of 6MeMP added to HClO4 
extractions of RBC lysate and freeze-dried pMNC and Molt-F4 cells were also 
determined. The recoveries of 6MeMP, under these conditions, were 85-96% for 
RBC, 89-97% for pMNC and 88-97% for Molt-F4. 
 
 
Enzyme kinetics 
 
Km and Vmax values for 6MP and SAM were calculated from Lineweaver-
Burke-plots to determine maximal substrate and co-substrate conditions for TPMT 
activity. The Km and Vmax values obtained from incubations with RBC, pMNC and 
Molt-F4 cells are presented in Table 1. From these results, the optimal 
concentrations of 6MP (2 mM) and SAM (50 µM) were calculated to measure TPMT 
enzyme activity in blood samples from patients and in Molt-F4 cells.   
 
 
Table 1. Km and Vmax for 6-mercaptopurine (6MP) and S-adenosylmethionine (SAM) calculated from 
Lineweaver-Burke plots in erythrocytes (RBC), peripheral blood mononuclear cells (pMNC) and Molt-
F4 cells 
 6MP SAM 
Cell type Km Vmax R2 Km Vmax R2 
RBC 0.54 mM 16.2 pmol/107 cells per hr 0.994 11.9 µM 15.7 pmol/107 cells per hr 0.9994 
pMNC 0.85 mM 10.4 pmol/106 cells per hr 0.985 16.4 µM 11.0 pmol/106 cells per hr 0.985 
Molt-F4 0.65 mM 14.5 pmol/106 cells per hr 0.995 6.65 µM 14.4 pmol/106 cells per hr 0.996 
R2 = coefficient of variance 
 
 
 TPMT activity was evaluated for linearity between product formation and 
incubation time. The plots showed a good linearity during the first 3 hrs of incubation, 
with variance coefficients of 0.986, 0.992 and 0.995 for RBC, pMNC and Molt-F4 
cells, respectively. Similar plots were made to study the linearity between product 
formation and number of cells used per assay. These plots also showed a very good 
correlation with the number of cells analysed (r = 0.984 for RBC, r = 0.994 for Molt-
F4 cells and r = 0.990 for pMNC). Linearity was observed between 5 x 107 and 10 x 
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107 RBC, 2 x 106 and 3 x 106 Molt-F4 cells, and 2 x 106 and 3 x 106 pMNC. Specific 
TPMT activities of RBC samples were expressed in pmol/107 cells per hr and those 
of pMNC and Molt-F4 cells in pmol/106 cells per hr.  
 
Two RBC samples were chosen to assess the within-run variation of the 
method. From these samples, the RBC-TPMT activity was measured 10 times during 
the day. The data for the two samples showed a mean ± SD of 15.0 ± 1.4 and 22.4 ± 
2.0 pmol/107 RBC per hr, respectively. 
 
The between day variation of the method was tested in samples from five 
persons. After allowing the enzyme reaction to proceed, the reaction was stopped, 
neutralized, centrifuged and the supernatant stored at either -230C or at -800C. The 
results from these experiments showed that the supernatants were stable for 1 week 
before HPLC analysis when stored at -230C: the initial TPMT activities were 17.2 ± 
1.6, 38.5 ± 2.4, 17.6 ± 2.1, 15.9 ± 1.4 and 12.2 ± 2.1 pmol/107 RBC per hr, 
respectively; the corresponding TPMT activities after 7 days were 19.2 ± 1.4, 36.4 ± 
2.1, 17.0 ± 1.8, 15.1 ± 2.5 and 12.8 ± 2.4 pmol/107 RBC per hr, respectively. 
However, storing the supernatant at -80oC resulted in only little change in measured 
activity even after 25 days, when the activities were 17.0 ± 2.2, 34.0 ± 2.6, 15.5 ± 2.4, 
15.6 ± 1.8 and 10.6 ± 1.6 pmol/107 RBC per hr, respectively.  
 
Finally, the HPLC-based TPMT assay was compared with the generally used 
radiochemical thin-layer chromatography (TLC)-based method.21 A fairly good 
correlation was observed between the two methods, with a correlation coefficient of 
0.935 (see Figure 2). 
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Figure 2.  (a) Comparison between the high-performance liquid chromatography (HPLC)-based 
method and the radiochemical assay. Thiopurine S-methyltransferase (TPMT) activity (both axes) is 
expressed in pmol/107 RBC per hr. Seven samples from patients were measured by both methods. 
The correlation coefficient between the two methods is 0.935. (b) Bland-Altman plot of TPMT activity 
{(radiochemical method + HPLC method)/2)} (x-axis) plotted against the difference in activity between 
the radiochemical assay and the HPLC-based assay (y-axis). Thiopurine S-methyltransferase (TPMT) 
activity (both axes) is expressed in pmol/107 RBC per hr. 
 
 
Comparison between erythrocyte TPMT activities expressed as 
amount per 107 cells and per mg protein 
 
 In the 10 patients with ALL and the 10 controls, we measured both the number 
of RBC and the protein content of the lysate. When TPMT activity was expressed in 
pmol/107 RBC per hr and pmol/mg protein per hr, a good correlation was observed 
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with a Spearman’s correlation coefficient of 0.741 (p<0.001; see Figure 3). However, 
it should be noted that with one of the higher values of the controls there was a 
seemingly significant difference between the RBC value and the protein value. 
 
 
Figure 3. Correlation of erythrocyte (RBC) thiopurine S-methyltransferase (TPMT) activities expressed 
in pmol/107 RBC per hr (x-axis) and pmol/mg protein per hr (y-axis).  ALL = acute lymphoblastic 
leukemia 
 
 
Reference values for erythrocyte TPMT activity in children and 
young adults 
 
The HPLC-based method was used to determine reference values of RBC-TPMT 
activities in a group of 103 children and young adults (0-18 years; 44 female and 59 
male). The mean ± SD value found for female subjects was 15.1 ± 4.8 pmol/10 RBC 
per hr and for male subjects was 15.8 ± 6.4 pmol/107 RBC per hr. For the whole 
reference population, a mean±SD value of 15.5 ± 5.7 pmol/107 RBC per hr was 
found. 
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Figure 4. Frequency distribution of baseline erythrocyte (RBC) thiopurine S-methyltransferase (TPMT) 
activities measured in the reference group of 103 children and young adults. TPMT activity is 
expressed in pmol/107 RBC per hr. 
 
 
The test results (P values) from two-way analysis of covariance showed no 
significant sex differences in TPMT activity (paired t-test P = 0.483). Also, no 
significant differences were observed in TPMT activities when comparing children 
and young adults of various ages.  
 
The frequency distribution of RBC-TPMT activity in the whole control group of 
male and female subjects is shown in Figure 4. The results are consistent with the 
polymorphism described by others.8,10,22 
 
 
Discussion 
 
Evidence exists that the genetic polymorphism of TPMT activity plays an 
important role during treatment with 6MP or azathioprine. There have been several 
reports of patients with TPMT deficiency developing severe hematological toxicity 
when treated with oral 6MP or azathioprine and most cases required a five- to tenfold 
dose reduction due to this toxicity.2,11,12,14,22 TPMT activity also appears to play a role 
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in the prognosis and survival of childhood ALL, reflecting the therapeutic efficacy of 
treatment with 6MP.2,11,12,22 
 
In view of the observations mentioned above, it is of importance to measure 
TPMT activity before starting thiopurine administration. Moreover, it may be useful to 
monitor TPMT activity during therapy, because its activity is often increased during 
therapy.18 For this purpose, we have developed the HPLC-based enzymatic 
procedure described above. The procedure enabled measurement of TPMT activity 
in RBC, pMNC, and leukemic cell lines and showed good reproducibility for all three 
types of cells. Furthermore, our results showed that the neutralized supernatants 
may be stored for up to 3 weeks at –80oC before HPLC analysis.   
 
In an earlier study,23 using a radiochemical TLC procedure, we could not 
measure pMNC-TPMT activity in nine out of 36 cases because these patients were 
leucopenic and we were unable to collect the necessary 5 x 106 cells for this assay. 
However, with the present HPLC-based method, we can perform the assays with 
only 2 x 106 cells. The HPLC-based method has other advantages over the 
radiochemical TLC method as well as its improved sensitivity. First, it is more reliable 
because it avoids the liquid-liquid or solid-phase extraction used in the radiochemical 
TLC method. Second, it is a non-radiochemical procedure, so it is more compliant 
with current environmental protection policies. Third, it is less time-consuming and 
has a quicker sample throughput compared with the radiochemical method.  
 
At present, for historical reasons, there is no uniform TPMT activity unit 
reported by laboratories and this is an issue that should be resolved. We chose to 
express TPMT activity based on the amount of RBC, since the RBC itself is the 
reactive unit. Expressing TPMT activity as pmol per ml RBC or per mmol hemoglobin 
is, in our opinion, unsatisfactory due to significant differences in hematocrit and in the 
number of RBC per ml blood in patients receiving chemotherapy, as described by 
Klemetsdal et al.24 In comparison with earlier studies, we have established reference 
values in pmoles per number of RBC. Additionally, we measured the RBC lysate 
protein content of a representative subset of samples to relate these determinations 
to the number of lysed RBC. The correlation appeared to be fairly good. 
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In a number of studies it has been reported that tissues derived from male 
subjects have approximately 10% higher TPMT activity than those from female 
subjects.25,26 However, the findings have not been confirmed either by other 
authors27,28 or by this study, in which no age- or sex-related differences were 
observed in our control group of 103 children and young adults. The distribution of 
RBC-TPMT activity in our reference group (see Figure 4) is consistent with the 
known polymorphism. We consider the ‘intermediate’ TPMT activity to range from 5.8 
to 10 pmol/107 RBC per hr (≤ 11.1th percentile), and individuals with such activity 
should provide specimens for mutation analysis.  The ‘high’ TPMT activities are 
considered to be > 10 pmol/107 RBC per hr (> 11.1th percentile). One child in the 
control group, a boy, had a very low TPMT activity of 1.6 pmol/107 RBC per hr; 
another boy had a very high activity of 50.7 pmol/107 RBC per hr.  
 
As mentioned earlier, various studies have shown that low activity of TPMT 
may be a cause of azathioprine- or 6MP-related bone marrow toxicity. Consequently, 
if an untreated patient is found to have a low TPMT activity, treatment should be 
initiated at a five- to tenfold lower dose of thiopurine than is used in patients with 
normal enzyme activity. The method described above is suitable for the rapid 
screening of such patients.  
 
 
 
Conclusion 
 
In conclusion, this paper describes an HPLC-based method that enables the 
measurement of TPMT activity to be made in large numbers of patients. It also 
describes TPMT activities measured using the method in a control group of 103 
children and young adults aged less than 20 years. The range of activities observed 
may be used to identify cases with TPMT deficiency or they may be compared 
directly with the reference intervals described by other authors.  
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To the Editor, 
 
Thiopurine S-methyltransferase (TPMT) is a methylating enzyme which is involved in 
the metabolism of thiopurines. The enzyme is known to exhibit an autosomal 
codominant polymorphism with 89-94% of all individuals studied having a high 
activity, 6-11% an intermediate activity and 0.3% having a very low or non-detectable 
activity. The gene encoding TPMT is localized on chromosome 6. Eight variant 
alleles of the gene are reported to be associated with decreased TPMT enzyme 
activity, and TPMT*3 mutations are the most prevalent.1,2 Heterozygotes and 
homozygotes for these alleles are at moderate and high risk, respectively, for 
thiopurine drug toxicity. In Caucasians and South West Asians, TPMT*3A (transitions 
G460A and A719G ) is the most prevalent mutant allele whereas in a Chinese, a 
Korean and an African population as well as an African-American population the 
TPMT*3C (A719G) mutation is more common. The TPMT*3A allele is believed to 
have arisen as a result of a TPMT*3B (G460A) mutation on an ancestral TPMT*3C 
variant allele.1  
 
From reviewing the literature on TPMT population studies and from our own 
genotyping, we note that 19 cases of TPMT*3B have been reported from a total of  
12 208 alleles, a frequency of 0.16%.3-7 The mutations TPMT*3A and TPMT*3C 
accounted for 4.00% (488 alleles) and 1.38% (168 alleles), respectively, of the total 
amount of alleles published.  
 
The A719G (TPMT*3C) mutation creates an AccI recognition sequence and 
the G460A (TPMT*3B) mutation destroys a MwoI site.2 Using the method described 
by Yates et al.8 we have screened 116 children who were or had been suffering from 
acute lymphoblastic leukemia (ALL); eight of these children were screened after 
presentation of toxicological features during thiopurine treatment. We also genotyped 
43 control children not suffering from any hematological disorders. Twenty children 
were found to carry one or two mutant alleles. Unexpectedly, we found two TPMT*3B 
heterozygotes and one patient homozygous for TPMT*3B (see Table 1). In view of 
the low occurrence of the TPMT*3B allele, we expected that these alleles were “mis-
diagnosed” and resulted from incomplete restriction endonuclease digestion. 
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Table 1. Results of mutation screening 
 
 
Mutations found 
First screening Second screening 
Patient 
carrying mutant 
alleles 
Cause of aberrant result 
TPMT*1/*3A TPMT*1/*3A 10  
TPMT*1/*3B TPMT*1/*3A 1 AccI 
TPMT*1/*3C TPMT*1/*3C 3  
TPMT*3B/*3B TPMT*3A/*3A 1 AccI 
TPMT*1/*3B TPMT*1/*1 1 MwoI 
TPMT*3A/*3A TPMT*3A/*3A 3  
TPMT*2/*3A TPMT*2/*3A 1  
    
TPMT*3B/*3C TPMT*1/*3A 2 One or two alleles 
affected? 
 
 
 
These patients were re-examined using a stringent restriction endonuclease 
digestion protocol. PCR products were desalted by micro-dialysis on Millipore VS 
type filters (Pall Corporation, Ann Arbor MI, USA) prior to an extended overnight 
digestion. In order to detect inhibitors of digestion, a dialysed PCR product was 
spiked with DNA known to contain appropriate restriction endonuclease sites.  Using 
this protocol, we confirmed that incomplete AccI digestion of the A719G mutation 
resulted in TPMT*3A alleles being mistaken for TPMT*3B alleles. Theoretically, 
having a TPMT*3A or a TPMT*3B allele could have implications for the residual 
TPMT activity and therefore for the amount of thiopurine tolerated. Expressing 
TPMT*3A and TPMT*3B in yeast, Tai et al.9 showed a 50-fold higher protein level for 
TPMT*3B, as compared with TPMT*3A. The Spearman rank correlation between 
erythrocyte TPMT activity and amount of TPMT protein in the erythrocytes was 0.99, 
which was highly significant. However, it is premature to conclude that this indeed is 
of clinical significance. 
 
Problems with partial digestion were however not limited to AccI: in one wild-
type patient partial digestion by MwoI of the wild-type G460 resulted in the 
misdiagnosis of a TPMT*3B/*1 heterozygote. To further prevent misdiagnosis of the 
TPMT*3B allele, positive and negative controls are needed. 
 
Since the occurrence of the TPMT*3B allele is so low, as it seems to occur 
with a frequency of less than 1:500, the allele cannot be considered to be a 
significant risk allele for thiopurine drug toxicity. By extension, since the TPMT*3B 
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allele occurs with an extremely low frequency, TPMT*3B/TPMT*3C compound 
heterozygotes (which cannot be discriminated from TPMT*3A heterozygotes by 
PCR) are unlikely to pose a significant diagnostic dilemma. However, one case of a 
TPMT*3B/TPMT*3C compound heterozygote has been reported recently and this 
finding seems to be significant, because the mutations were characterized at the 
cDNA level using a hybridization probe assay.7 However, the TPMT*3B and 
TPMT*3C mutations in this patient were shown to occur alone on assayed cDNA 
clones and in our opinion this does not provide conclusive evidence of the existence 
of the TPMT*3B genotype. The anchor probes used in the assay were designed for 
genomic DNA, spanned intron-exon boundaries and were thus not fully 
complementary to the TPMT cDNA target. In addition, the results were not confirmed 
by DNA sequencing.  
 
In our study we found patients with a homozygous TPMT*3A mutant genotype 
had TPMT activities ranging from non-detectable to 2.8 pmol/107 RBC per hr. We 
also found two apparent TPMT*3B / TPMT*3C compound heterozygotes, 
accompanied with very low TPMT activities of 2.2 and 3.2 pmol/107 RBC per hr. To 
investigate whether one or two alleles were affected, PCR products were cloned 
using the pGEM-T Kit (Promega Corporation, Madison WI, USA). These PCR 
products of 630 bp were obtained by amplifying cDNA with a forward primer located 
in exon 5 and a reverse primer being located in exon 10, thus containing both sites of 
interest. One wild-type was included as a control. Plasmid DNA was isolated and 
screened for the presence of the inserted fragment. The genotype of the plasmid 
DNA samples with the correct inserted fragment was examined by double digestion 
with AccI and MwoI. Both mutant cases appeared to be TPMT*3A heterozygotes.  
 
With increasing awareness of the role of TPMT in thiopurine drug metabolism, 
we anticipate a considerable increase in requests for TPMT genotype. We hope that 
our experience will serve as a salutary warning to TPMT genotype service providers. 
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Abstract 
 
Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme, catalysing S-
methylation of aromatic and heterocyclic sulphhydryl compounds. TPMT activities 
and genotypes have been determined in patients with acute lymphoblastic leukemia 
(ALL) and in control children. Median red blood cell (RBC) TPMT activity in ALL 
patients at diagnosis was significantly lower than in controls (median 11.5 pmol/107 
RBC per hr; range 1.7-30.7; n=191 vs. 14.6 pmol/107 RBC per hr; range 1.6-50.7; 
n=140). This reduction of TPMT activity in ALL patients was not due to differences in 
the frequency of mutations in the TPMT gene. In concordance with other authors, we 
found a higher TPMT activity during maintenance treatment with 6-mercaptopurine 
(6MP) than at diagnosis and in controls. However, we observed that TPMT activity 
was already significantly increased after the induction therapy, before the patients 
received 6MP (median 17.5; range 3.9-40.3 pmol/107 RBC per hr; n=139). In vitro 
experiments indicate that the early increase of TPMT activity during treatment may 
be explained by the use of antifolates, e.g., methotrexate and trimethoprim.  
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Introduction 
 
 6-Mercaptopurine (6MP) is a hypoxanthine analogue. Metabolic activation 
occurs by its conversion to thioinosine monophosphate (thio-IMP). This reaction is 
catalysed by hypoxanthine-guanine phosphoribosyltransferase in the presence of 
phosphoribosyl pyrophosphate (PRPP) as a cosubstrate. Thio-IMP can be converted 
to thioguanine nucleotides (TGNs) which are incorporated into DNA and RNA to 
exert cytotoxicity. A second cytotoxic pathway is the methylation of thio-IMP to 
methylthio-IMP by thiopurine-S-methyltransferase (TPMT), a cytosolic enzyme 
catalysing S-methylation of aromatic and heterocyclic sulphhydryl compounds. 
Methylthio-IMP has been shown to inhibit the purine de novo synthesis.1 By contrast, 
6MP can be methylated to methyl-6MP. This reaction is part of the catabolic 
pathway, since methyl-6MP cannot be converted to active compounds.  
 
 TPMT exhibits autosomal codominant polymorphism with 89-94% of the 
population having a high activity.2,3 One out of 300 individuals has a very low or non-
detectable TPMT activity and 6-11% of the population show an intermediate activity.  
The gene encoding TPMT is localised on chromosome 6.4 Polymerase chain reaction 
(PCR)-, single strand conformational polymorphism (SSCP)-, denaturing high-
performance liquid chromatography (DHPLC) and hybridisation probe assays have 
been developed to detect TPMT mutations.5-10 Mutations in the TPMT gene often 
lead to an enzyme which is more susceptible to proteolysis resulting in a faster 
degradation of the enzyme.11 Many studies have been conducted in genotyping 
individuals. TPMT*3A mutations are the most prevalent ones with an allele frequency 
of 4.0 %. In addition, TPMT*3C alleles have been found in some cases (1.4%). Other 
mutations occur rarely. In 93.7% of the cases, wild-type alleles were found.12 Similar 
findings have been described in an ALL population by McLeod and colleagues.13 
 
 Knowledge of TPMT activity is of special importance when patients are treated 
with 6-thiopurines e.g., 6MP, 6-thioguanine or azathioprine. Lennard and colleagues 
have shown that when TPMT activity is very high, and, consequently, the RBC-TGN-
concentration is relatively low, treatment failure occurs more often.14 They observed 
a lower TPMT activity in children suffering from ALL at diagnosis compared with 
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healthy children.15 TPMT activity significantly increased during maintenance 
treatment of patients with ALL compared with the activity at diagnosis. After 
termination of treatment, TPMT activity decreased to control values.16 
 
McLeod and colleagues have shown that the TPMT activity in RBC at 
diagnosis correlates well with the TPMT activity in lymphoblasts at diagnosis.16 
Furthermore, a good correlation of TPMT activity in RBC and lymphocytes in control 
subjects has been shown.17 TPMT assays are mainly performed in RBC due to the 
low number of white blood cells (WBC) during treatment of ALL.  
 
 In this study, we monitored the dynamics of RBC-TPMT activity at diagnosis, 
and during and after therapy in patients with ALL. Monitoring TPMT activity may be of 
benefit to improve thiopurine therapy. Additional experiments were performed to 
investigate the biochemical mechanism causing increase in TPMT activity during 
drug therapy compared with TPMT activity at diagnosis. A group of patients and 
controls were also genotyped to look for genotype/phenotype correlations.  
 
 
Materials and methods 
 
Chemicals 
 
 6MP, 6-methyl mercaptopurine (6MeMP), S-adenosyl methionine (SAM), 
allopurinol, dithiotreitol (DTT), methotrexate (MTX), vincristine, dexamethasone, L-
asparaginase and trimethoprim were obtained from Sigma Chemicals (St Louis MO, 
USA). Perchloric acid (PCA) was purchased from Fluka (Buchs, Switzerland). 
Methanol and acetonitrile were obtained from Labscan (Dublin, Ireland). Glutamax-1, 
gentamycin and deoxynucleoside triphosphates (dNTPs) were purchased from 
Invitrogen (UK). Sodium pyruvate was obtained from BDH Chemicals Ltd (UK). 
Potassium dihydrogenphosphate, dipotassium hydrogenphosphate, 
dimethylsulphoxide and L-methionine were obtained from Merck (Darmstadt, 
Germany). Fetal bovine serum was obtained from Integro BV (Dieren, the 
Netherlands). Isolation of genomic DNA was performed with the Puregene Genomic 
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DNA Isolation Kit (Gentra Systems, Minneapolis MN, USA). Primers were all 
purchased from Invitrogen Corporation (Carlsbad CA, USA). Restriction enzymes 
used were purchased from New England Biolabs (Beverly MA, USA), except for Mse 
I, which was obtained from Invitrogen Corporation (Carlsbad CA, USA). Primers and 
restriction enzymes used are listed in Table 1.  
 
Patients’ and control material 
 
Patients 
Patients’ blood samples were obtained from children with ALL included in the DCOG, 
formerly the Dutch Childhood Leukemia Study Group (DCLSG)-ALL-9 protocol after 
written informed consent of the patients and/or their parents or guardians (Table 2). 
This protocol excluded patients with mature B-ALL. Patients were stratified into two 
treatment regimens: non-high-risk (NHR) and high-risk (HR). Criteria for HR were: 
WBC count > 50*109/l, T-cell leukemia, broadened mediastinum, initial central 
nervous system (CNS) or testicular involvement, presence of a t(9;22) or a bcr-abl- 
rearrangement, presence of a t(4;11) or a 11q23 aberration with an mll-
rearrangement. Patients who did not meet any of these criteria at diagnosis were 
treated according to the NHR protocol, which is similar to the DCLSG-ALL-6 protocol 
except for two changes.18 In the ALL-9 protocol triple intrathecal therapy is 
administered. And 4 intravenous (i.v.) Paronal® (L-asparaginase) infusions are given 
instead of the 14 Crasnitin® (L-asparaginase) infusions in ALL-6. Maintenance 
treatment consisted of alternating cycles of 2 weeks vincristine and dexamethasone, 
and 5 weeks of oral 6MP (50 mg/m2 daily) and oral methotrexate (30 mg/m2 weekly) 
until week 109. TPMT activity of children with NHR-ALL was determined at diagnosis 
(week 0), after induction treatment (week 6), after the prophylactic treatment of the 
CNS with 3 weekly medium-dose MTX infusions, i.e. at the start of maintenance 
therapy (week 11), during maintenance therapy (weeks 25, 53, 81 and 109) and one 
year after cessation of treatment.  
 
The induction therapy of HR patients (weeks 0-6) was similar to that of NHR 
patients with the addition of 4 doxorubicin injections in the first 4 weeks and 4 weekly 
intrathecal triple injections in case of CNS disease at diagnosis. This was followed by 
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a period of 8 weeks of prophylactic CNS treatment (weeks 6-14) with oral 6MP (50 
mg/m2) and 4 high-dose MTX (3 g/m2) infusions. Intensification treatment I (weeks 
15-23) consisted of daily oral 6MP (50 mg/m2), weekly i.v. L-asparaginase, every 3 
weeks oral dexamethasone (7 days) and vincristine and daunorubicin. In weeks 24-
32 six intensification-courses with cyclophosphamide and cytosine-arabinoside 
(ARA-C) were given. During maintenance treatment (weeks 33-109), MTX was 
administered i.v. TPMT activity of children with HR-ALL was determined at week 0, 6, 
15, 32 and during maintenance therapy (weeks 53, 81 and 109) and one year after 
cessation of treatment.  
 
During maintenance treatment, blood was sampled after a 5-weeks period of 
6MP and MTX administration. During the entire treatment period until 3 months after 
cessation of ALL treatment, patients also received oral low dose cotrimoxazole, a 
mixture of sulphomethoxazole and trimethoprim (15 and 3 mg/kg, respectively, 3 
days weekly), to prevent Pneumocystis carinii pneumonia. 
 
 
Controls 
 As control material, heparinised blood was used from control pediatric 
patients, after their written informed consent and/or after consent of their parents or 
guardians. These patients were non-critically ill children from the outpatient clinic of 
our department of Pediatrics at the University Medical Center, Nijmegen. They were 
not suffering from either hematological, immunological or nephrological diseases, 
and were also not treated with thiopurines or other antimetabolites, e.g., antifolates. 
 
 
Sample isolation 
 
 Within 24 hours after blood sampling, RBC and WBC were isolated by density 
gradient centrifugation, as described earlier in Ref. 19.19 The mononuclear fraction 
(pMNC) was used for mutation analysis and the RBC were lysed for TPMT activity 
measurements, following the procedure as described in Ref. 20.20 RBC and WBC 
were counted with an automated cell counter (Sysmex F520, Goffin, Meyvis, Tiel, the  
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Table 1. Primers and restriction enzymes used for mutation detection of the thiopurine S-methyltransferase (TPMT) gene. 
 
Mutation   Primer   Sequence    PCR fragment-  Restriction Restriction 
      5’→3’     length   enzyme fragment length 
TPMT*2  P2FW   gta tga ttt tat gca ggt ttg   254 bp   
   P2FM   gta tga ttt tat gca ggt ttc 
   P2R   taa ata gga acc atc gga cac 
 
TPMT*3B  P3F   agg ctc cta aaa cca tga ggg  317 bp   Mwo I  77, 240 bp 
   P3R   gta tac taa aaa att aag aca gc  
 
TPMT*3C  P3CF   cag gct tta gca taa ttt tca att cct c 293 bp   Acc I  86, 207 bp 
   P3CR   tgt tgg gat tac agg tgt gag cca c 
 
TPM*3D  P2FW   gta tga ttt tat gca ggt ttg   254 bp   Apo I  49, 74, 131 bp 
   P2FM   gta tga ttt tat gca ggt ttc 
   P2R   taa ata gga acc atc gga cac 
 
TPMT*4  P4FW   ttt aac atg tta ctc ttt ctt gtt tca a  209 bp 
   P4FM   ttt aac atg tta ctc ttt ctt gtt tca g 
   P3CR   tgt tgg gat tac agg tgt gag cca c 
 
TPMT*5  P5F   cta ctc gga tac tga ggt ac  233 bp   Mse I  110, 123 bp 
   P5R   ctt gta tcc caa gtt cac tg  
 
TPMT*6  P6FW   cct ggg aaa gaa gtt tca ga  188 bp 
   P6FM   cct ggg aaa gaa gtt tca gt 
   P6R   gac agt caa ttc ccc aac tt 
 
TPMT*7  P7FW   ggt gat gct ttt gaa gaa cga cat  149 bp 
   P7FM   ggt gat gct ttt gaa gaa cga cag 
   P3CR   tgt tgg gat tac agg tgt gag cca c 
 
bp = base pairs, PCR = polymerase chain reaction 
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Table 2. Treatment phases and measure points during treatment of acute lymphoblastic leukemia (ALL) patients according to the Dutch Childhood Leukemia 
Study Group (DCLSG)-ALL-9-protocol 
 
NHR HR  
Treatment 
period 
(weeks) 
Cytostatics Sampling 
week 
Treatment 
period 
(weeks) 
Cytostatics Sampling 
week 
Induction 
treatment 
0-6 Dexamethasone (6 mg/m2, p.o.) 
Vincristine (2 mg/m2, i.v.) 
L-Asparaginase (6000 IU/m2, i.v.) 
Intrathecal therapy (MTX, diadreson-
F aquosum and cytosine-
arabinoside) 
0 
 
 
 
 
 
6 
0-6 Dexamethasone (6 mg/m2, p.o.) 
Vincristine (2 mg/m2, i.v.) 
Daunorubicine (25 mg/m2, p.o.) 
L-Asparaginase (6000 IU/m2, i.v.) 
Intrathecal therapy (MTX, diadreson-F 
aquosum and cytosine-arabinoside) 
0 
 
 
 
 
 
6 
Prophylactic 
CNS 
treatment 
7-10 MD-MTX (2 g/m2, p.i.) 
Intrathecal therapy 
 
 
11 
7-14 HD-MTX (3 g/m2, p.i.) 
Intrathecal therapy  
6-MP (50 mg/m2, p.o.) 
 
 
15 
 
Intensification  
treatment I 
    
15-24 
 
6-MP (50 mg/m2, p.o.) 
Dexamethasone (6 mg/m2, p.o.) 
Vincristine  (2 mg/m2, i.v.) 
Daunorubicine (25 mg/m2, i.v.) 
L-Asparaginase (6000 IU/m2, i.v.) 
Intrathecal therapy  
 
Intensification  
treatment II 
   25-31 6 courses of: Cytarabine (4x80 mg/m2, i.v.), 
Cyclophosphamide (4x80 mg/m2, i.v.) 
 
32 
 
Maintenance 
treatment 
 
11-109 
 
Alternating:  
2 weeks: Intrathecal therapy 
Dexamethasone (6 mg/m2, p.o.) 
Vincristine (2 mg/m2, i.v.) 
 
and 5 weeks: 6-MP (50 mg/m2, p.o.) 
MTX (30 mg/m2, p.o.) 
 
 
25 
 
53 
 
81 
 
109 
 
32-109 
 
Alternating: 
2 weeks: Intrathecal therapy 
Dexamethasone (6 mg/m2, p.o.) 
Vincristine (2 mg/m2, i.v.) 
 
and 5 weeks: 6-MP (50 mg/m2, p.o.) 
MTX (30 mg/m2, i.v.) 
 
 
 
 
53 
 
81 
 
109 
 
NHR = non high risk, HR = high risk, CNS = central nervous system, p.i. = per infusion, p.o.= orally, i.v. = intravenously, MTX = methotrexate. Intrathecal therapy during maintenance 
treatment is given until week 60 (NHR group) or 81 (HR group) of the DCLSG-ALL-9-protocol.
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Netherlands). RBC were washed three times with phosphate-buffered saline and 
then lysed in three volumes of ice cold water. Subsequently, the lysate was 
centrifuged at 14,000 g for 10 min at 4°C to remove cellular debris. The supernatant 
was kept at -80°C until analysis, as were the pMNC. 
 
 
In vitro experiments 
 
 The effects of various drugs, used during induction treatment of ALL, on TPMT 
activity were studied in Molt F4-cells, a human T-lymphoblastic cell line. Conditions of 
cell culture were as described by Stet and colleagues,21 with some modifications. The 
cells were cultured in Roswell Park Memorial Institute (RPMI) 1640 medium with 
Glutamax-1 supplemented with 10% fetal calf serum, 2 mM sodium pyruvate and 
gentamycin (50 µg/ml). Twenty four hours prior to the start of the experiments, 
logarithmically growing cells were seeded in a concentration of 0.3*106 cells per ml. 
Drugs were added to the medium in clinically relevant concentrations: for vincristine 
0.0012; 0.012; 0.120 µM, for dexamethasone 0.0025; 0.025; 0.25 µM, for L-
asparaginase 0.001; 0.01; 0.1 IU/ml, for trimethoprim 0.24; 2.4; 24 µM, and for MTX 
0.005; 0.01 and 0.1 µM. Drugs were added as single doses in 1/100 volume. Blanks, 
i.e. no drugs added, were included (indexed as 100% in each experiment).  
Furthermore, we investigated the effect of methionine, a precursor for SAM, on the 
TPMT increase observed after incubation with trimethoprim. Cells were incubated 
with or without the addition of trimethoprim (2.4 µM), together with or without the 
addition of 1.5 mM methionine. After 24 hours of incubation, cells were harvested and 
counted in a Coulter Counter (model Z1, Coulter Electronics, Luton, UK). Cell viability 
was determined by the trypan blue exclusion test, and TPMT activity was measured 
(see below). Experiments were performed in triplicate.  
 
 
Determination of the TPMT activity 
 
 Control and patients’ TPMT activities were measured as described by Keizer-
Garritsen and colleagues20 and expressed as pmol 6MeMP formed per 107 RBC per 
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hour of incubation. In Molt F4-cells, TPMT activity was expressed as pmol 6MeMP 
formed per 106 viable Molt F4-cells per hour of incubation. 
 
 
Screening on TPMT mutations 
 
 Each assay was done using 75 ng genomic DNA. The standard PCR protocol 
consisted of a denaturation step (95 oC for 5 min) followed by 30 cycles of 
denaturation (94 oC for 1 min), annealing (specific annealing temperature for 2 min) 
and extension (72 oC for 1 min). The final extension was performed at 72 oC for 7 
min.  
 
 TPMT*2, TPMT*3A, TPMT*3B and TPMT*3C were screened according to the 
method described by Yates and colleagues,5 with slight modifications. To detect the 
TPMT*2 mutation, we used an allele-specific PCR. The PCR reaction was carried out 
in 50 µl of a solution containing buffer (20 mM Tris-HCl, 50 mM KCl; pH 8.5), 4 mM 
MgCl2, 1 mM dNTPs, 0.5 µM of primers P2FW and P2R for the wild-type allele or 
primers P2FM and P2R for the mutant allele and 1 U Taq polymerase (Life 
Technologies, Scotland). Annealing temperature during amplification was 57 °C. 
Wild-type or mutant DNA fragments were selectively amplified resulting in fragments 
lengths of 254 base pairs (Table 1).  TPMT*3A, containing the TPMT*3B mutation 
(G460A) and the TPMT*3C mutation (A719G) on one allele, is detected by a 
restriction enzyme analysis. The PCR assay to detect TPMT*3B was carried out in 50 
µl of a solution containing buffer G (Invitrogen; 60 mM Tris-HCl, 15 mM ammonium 
sulphate, 2.5 mM MgCl2, pH 9.0), 1 mM dNTPs, 0.4 µM of each primer P3F and P3R, 
and 1 U Taq polymerase. The annealing temperature was 53°C. 10 µl of PCR 
product were used for digestion with 1 U Mwo I. For optimal digestion, the samples 
were incubated overnight at 60°C. The PCR assay to detect TPMT*3C was carried 
out in 50 µl of a solution containing buffer I (Invitrogen; 60 mM Tris-HCl, 15 mM 
ammonium sulphate, 1.5 mM MgCl2, pH 9.5), 1 mM dNTPs, 0.4 µM of each primer 
P3CF and P3CR, and 1 U Taq polymerase. The annealing temperature was 57°C. 10 
µl of PCR product were used for digestion with 1 U Acc I. For optimal digestion, the 
samples were incubated overnight at 37°C. 
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 We also developed a PCR assay for TPMT*3D, TPMT*4, TPMT*5, TPMT*6 
and TPMT*7. To detect TPMT*3D fragments, containing a third mutation (G292T) on 
a TPMT*3A allele, the TPMT*2 PCR products (with primers P2FM and P2R) were 
used. Digestion of the PCR products with 1 U Apo I for 2 hours at 50°C provided 
three fragments with lengths of 131, 74 and 49 bp for wild-type alleles. PCR products 
containing the G292T mutation will be cut in two fragments (131 and 123 bp). 
TPMT*4, a G→A splice site mutation of intron 9, could be detected using an allele 
specific PCR. The PCR reaction mixture contained buffer A (Invitrogen; 60 mM Tris-
HCl, 15 mM ammonium sulphate, 1.5 mM MgCl2; pH 8.5), 1 mM dNTPs, 0.4 µM of 
primers P4FW and P3CR for the wild-type allele or primers P4FM and P3CR for the 
mutant allele, and 1 U Taq polymerase. The annealing temperature was 57°C. Wild-
type or mutant DNA fragments were selectively amplified resulting in fragment 
lengths of 209 base pairs. TPMT*5 (T146C mutation) could be detected using 
restriction enzyme analysis. The PCR reaction mixture contained buffer A, 1 mM 
dNTPs, 0.4 µM of each primer P5F and P5R, and 1 U Taq polymerase. Annealing 
temperature was 55°C. Digestion of the PCR product with 1 U MseI for 2 hours at 
37oC resulted in 2 bands of 110 and 123 bp for the wild-type allele; mutant alleles will 
not be cut. To detect TPMT*6, an A539T mutation, we used an allele-specific PCR. 
The PCR reaction mixture contained buffer D (Invitrogen; 60 mM Tris-HCl, 15 mM 
ammonium sulphate, 3.5 mM MgCl2; pH 8.5), 1 mM dNTPs, 0.4 µM of each primer 
P6FW and P6R for the wild-type allele or P6FM and P6R for the mutant allele, and 1 
U Taq  polymerase. Annealing temperature was 55°C. Amplification resulted in a 
fragment of 188 bp. TPMT*7, a T681G mutation, was detected by selective 
amplification as well. The PCR reaction mixture contained buffer A, 1 mM dNTPs, 0.4 
µM of each primer P7FW and P3CR for the wild-type allele or P7FM and P3CR for 
the mutant allele, and 1 U Taq polymerase. Annealing temperature was 55°C. 
Amplification resulted in a PCR fragment of 149 bp. All PCR fragments were 
separated on a 3% agarose gel. We decided not to include screening for mutation 
TPMT*8 as this is not a common mutation and the costs of the restriction enzyme 
needed (Mae II) are high. 
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Statistics 
 
 Ages in the control population and patients with ALL at diagnosis were 
compared using the Students’ t-test. Differences in TPMT activities in these groups, 
and both genders in the leukemic patient group were calculated using the Wilcoxon 
W test. The relation of TPMT activity with age was established with Spearman’s 
correlation analysis. Intrapatient differences of RBC TPMT activity at diagnosis, 
during ALL treatment and one year after cessation of treatment were calculated by 
means of the Wilcoxon Signed Ranks Test. The gender data in control and the ALL 
population were compared using the χ2 test, whereas the difference in prevalence of 
mutations in both groups was calculated using the Fisher’s Exact Test. TPMT 
activities in the control cells and the cells incubated with drugs were compared using 
the non-parametric Wilcoxon W test.  
 
 
Results 
 
TPMT activity in a control population and patients diagnosed with 
ALL 
 
 TPMT activities in control children were compared with those in patients with ALL 
at diagnosis and during treatment. With respect to gender, no significant differences 
were observed in controls (n=122; 51 females and 71 males) and in patients with ALL 
at diagnosis (n=173; 57 females and 116 males; χ2=2.712; P=0.100). Mean age in 
the control group was 8.6 ± 5.4 years whereas the mean age in the ALL group at 
diagnosis was 5.9 ± 4.1 years (P<0.001). The mean ages in both groups were 
different, but in an earlier study we observed no differences in control TPMT activities 
concerning both gender or age.20 In the patients monitored in this study, TPMT 
activity was not related with age (see Figure 1) nor gender. Median TPMT activity in 
male patients was 12.4 (range 1.7-30.7), in females 12.8 (range 5.8-30.4) pmol/107 
RBC per hr (P=0.841). Control RBC-TPMT activity showed an overall median activity 
of 14.6  (range 1.6-50.7) pmol/107 RBC per hr; n=140). The median TPMT activity in 
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patients with ALL at diagnosis was significantly lower than control values (11.5; range 
1.7-30.7) pmol/107 RBC per hr; n=191; P<0.001).  
 
 
 
Figure 1. Scatter diagram of thiopurine S-methyltransferase (TPMT) activity at diagnosis and age in 
patients with acute lymphoblastic leukemia (ALL). Spearman’s correlation coefficient was -0.070; 
P=0.419. TPMT activity is expressed in pmol/107 RBC per hr; age in years. 
 
 
TPMT mutations 
 
 In Figure 2, the genotype/phenotype correlations are shown for the controls 
and children with ALL. Forty three controls and 109 children with ALL have been 
genotyped. We found one child in each group to be homozygous for TPMT*3A. The 
TPMT activities of these children were 1.6 and 1.8 pmol/107 RBC per hr. Two of the 
controls showed a heterozygous genotype (one TPMT*1/*2 and one TPMT*1/*3A), 
whereas twelve patients with ALL carried one mutant allele. Nine of these patients 
showed a TPMT*1/*3A and three a TPMT*1/*3C genotype. All children possessing 
one or two mutant alleles had an RBC-TPMT activity below 15 pmol/107 RBC per hr.  
 
 In ALL patients at diagnosis, the median TPMT activity was significantly higher  
in the wild type (TPMT*1/*1) compared with the heterozygotes: 12.0 (range 3.2-30.4;  
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Figure 2. Correlation of TPMT genotype and phenotype in 109 children with ALL at diagnosis and 43 
controls. TPMT activity is expressed as pmol/107 RBC per hr. “P” indicates patients with ALL, “C” 
controls. Horizontal lines represent the median activities. 
 
 
n=95) vs. 7.5 (range: 1.7-13.0; n=14) pmol/107 RBC per hr, respectively (P=0.002). 
The frequency of mutant alleles as shown in Table 3, was not significantly different in 
controls compared with the ALL population (P=0.254). The median TPMT activity of 
the wild-type controls (15.1; range 5.8-50.7 pmol/107 RBC per hr; n=40) is higher 
compared with the TPMT activity of the wild-type of patients with ALL at diagnosis 
(12.0; range 3.2-30.4 pmol/107 RBC per hr; n=95; P=0.005). 
 
Table 3. Allele frequencies found in controls and children with ALL.  
 
Alleles Control population 
(n, %) 
ALL population  
(n, %) 
*1 82 (95.3) 204 (93.6) 
*2 1 (1.2) 0 
*3A 3 (3.5) 11 (5.0) 
*3C 0 3 (1.4) 
TOTAL 86 218 
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TPMT activity in patients during ALL treatment  
 
 
 TPMT activities during the various treatment phases in both the NHR (see Figure 
3a) and HR groups (see Figure 3b) are shown. In the total group (NHR+HR), TPMT 
activity significantly increased compared with the value at diagnosis during the first 
six weeks of treatment to a median TPMT activity of 17.5 (range: 3.9-40.3) pmol/107 
RBC per hr (n=111; P<0.001), which is 176% (range: 30 - 854%) compared with the 
level at diagnosis in the same patients.  
 
 TPMT activity was even significantly higher at this treatment stage than control 
values (P<0.001). During maintenance treatment, TPMT activity was still significantly 
increased, compared with that at diagnosis and control values, and remained stable 
during this whole treatment period (see Figure 3). At the end of treatment (week 109), 
values were still significantly higher compared with diagnosis (P<0.001). One year 
after cessation of treatment, the TPMT activity had normalised to control patient 
values (12.8; range: 8.2-23.7 pmol/107 RBC per hr; n=17; P=0.672).  
Interestingly, a transient, but statistically significant TPMT decrease was observed in 
HR patients at week 32 of ALL treatment (P=0.043) compared with TPMT activity at 
week 15. 
 
Influence of RBC transfusions on TPMT activity 
 
 In a subgroup of 29 homozygous wild-type patients, treated in our pediatric 
department, the influence of RBC transfusions on the median TPMT activity at 
diagnosis was studied in more detail. Thirteen of 29 patients were transfused within 
one week prior to diagnosis, blood sampling and initiation of therapy. The median  
TPMT activity of these transfused patients was not higher than in the patients who 
did not get an RBC transfusion in this stage: activities were 10.5 (range 3.2-15.9) 
vs.11.1 (range 1.7-19.8) pmol/107 RBC per hr, respectively (P=0.878). Thus, for 
TPMT analyses in a group, RBC tranfusions do not play a significant role.  
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Figure 3. TPMT activity during ALL treatment; (a) non-high risk (NHR) patients, (b) high-risk (HR) 
patients. Activity is expressed as pmol/107 RBC per hr. Horizontal lines represent the median TPMT 
activity, the dots represent the individual values. The category axis indicates the week of sampling. 
Number of patients are given as follows: time point (n). Concerning the NHR patients: week 0 (125), 
week 6 (88), week 11 (94), week 25 (105), week 53 (87), week 81 (51), week 109 (35), one year after 
cessation of treatment (13). Concerning the HR patients: week 0 (66), week 6 (51), week 15 (51), 
week 32 (41), week 53 (34), week 81 (25), week 109 (15), one year after cessation of treatment (4). 
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Influence of drugs on TPMT activity 
 
 We studied the effects of drugs administered during the first six weeks of ALL 
treatment, on Molt F4-cells in vitro. The effects on TPMT activity of different 
concentrations of these drugs are shown in Figure 4. TPMT activity in the untreated 
cells was 18.1 ± 2.2 pmol/106 Molt- F4 cells per hr. Following an incubation of the 
cells with 2.4 µM trimethoprim, a significant increase to 148% was observed (actual 
TPMT activity: 26.8 ± 4.7 pmol/106 Molt-F4 cells per hr; P=0.004; n=6). The increase 
could be partly counteracted by simultaneous addition of methionine (1.5 mM) to the 
medium (20.2 ± 2.2 pmol/106 Molt-F4 cells per hr, increase to approximately 112%). 
TPMT activity was increased to approximately 147% when cells were incubated with 
0.01 µM MTX (25.5 ± 3.9 vs. 17.4 ± 3.6 pmol/106 Molt-F4 cells per hr in the blank; 
n=10; P<0.001). Methionine alone also resulted in an enhancement of TPMT activity 
in Molt F4-cells (23.6 ± 2.1 pmol/106 Molt-F4 cells per hr). Vincristine, 
dexamethasone and L-asparaginase did not appear to have a stimulating effect on 
TPMT activity. On the contrary, at increasing concentrations these drugs inhibited 
TPMT activity. 
 
 
Discussion 
 
Increase of TPMT activity before 6MP administration 
 
 TPMT activities in children with ALL have been monitored from diagnosis 
throughout treatment and after cessation of therapy. In most patients, we found -in 
concordance with other authors- a very prominent increase in TPMT activity during 
ALL treatment. However, we have shown by in vitro experiments that the increase in 
TPMT activity was presumably attributable to antifolates, and not to thiopurine 
treatment. Capdeville and colleagues observed a higher TPMT activity at the start of 
the maintenance treatment, compared with that detected at a later phase of 
treatment.22 However, these patients were not monitored before the onset of 
chemotherapy. We have shown that the increase of TPMT activity already occurred 
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during the first six weeks of induction treatment, i.e. before 6MP is administered to 
the patients.  
 
 
 
Figure 4. TPMT activity after incubation of Molt F4-cells with various concentrations of several drugs. 
TPMT activity is given as mean percentage of blank (no drugs added) of triplicate measurements. 
Error bars represent the standard deviations. “H” = high concentration, “M” = medium concentration, 
”L” = low concentration of the drug administered. For the concentrations used: see Materials and 
Methods. Viability of the cells was 75-98%, except for L-asparaginase incubations: this was 57% and 
48% for “M” and “L”, respectively. 
 
 
 In a subgroup of patients, we showed that median TPMT activity of the children 
who were transfused just before diagnosis was similar to that of children who did not 
get a RBC transfusion. This observation excluded the possibility that the TPMT 
increase was attributable to RBC transfusions. 
 
 It should also be taken into account that part of the observed increase of TPMT 
activity may be due to a recovered erythropoiesis by drug treatment, resulting in a 
higher percentage of young RBC compared with at diagnosis. Lennard and 
colleagues pointed out, younger RBC have higher TPMT activity than matured 
RBC.15 
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 After the initial increase in TPMT activity, we did not see a further rise of TPMT 
activity in ALL patients after the prophylactic treatment of the CNS with MTX 
infusions and during maintenance treatment (Figure 3), indicating that a steady state 
had been reached. In the HR patients, we observed a transient decline of TPMT 
activity after the second intensification treatment with cyclophosphamide and 
cytosine arabinoside, although the activity was still higher than at diagnosis. The 
mode of MTX administration (p.o. in the NHR group, i.v. in the HR group) did not lead 
to a difference in TPMT activity during maintenance therapy.  
 
 We could demonstrate that treatment with 6MP is not the cause of the rise in 
TPMT activity in our patients. Which of the drugs used during induction treatment 
would be responsible for the enhancement was investigated in Molt F4 cells. These 
cells were incubated in vitro with drugs given during the first six weeks of treatment, 
i.e. the antifolates (trimethoprim used as PCP prophylaxis, starting directly after 
diagnosis, and intrathecal MTX), vincristine, dexamethasone and L-asparaginase. 
The antifolates had an enhancing effect on TPMT activity, whereas the other three 
drugs did not increase TPMT activity. The rise in TPMT activity, caused by these 
antifolates, may be due to their inhibitory effect on the transmethylation pathway 
(Figure 5). MTX as well as trimethoprim are known inhibitors of dihydrofolate 
reductase, 23,24 and may inhibit synthesis of SAM. Moreover, the formation of 
adenosine triphosphate (ATP), necessary for the conversion of methionine to SAM, is 
inhibited by antifolates because these compounds can inhibit the purine de novo 
synthesis.25-28 As a consequence, less SAM would be available for methylation 
reactions, resulting in a higher TPMT activity as a compensatory mechanism. This 
hypothesis is supported by our observation in vitro that methionine reduced the 
TPMT enhancement in Molt-F4 cells by trimethoprim. The enhancement was not 
completely reversed by methionine, probably because ATP remains the limiting 
factor. Whether this hypothesis is justified, should be studied further. 
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Figure 5. The transmethylation pathway; thio-IMP = thioinosine monophosphate; methylthio-IMP =  
methylthioinosine monophosphate, THF = tetrahydrofolic acid, DHF = dihydrofolic acid, MTX = 
methotrexate, TPMT = thiopurine methyltransferase, DHFR = dihydrofolic acid reductase, ATP = 
adenosine triphosphate. 
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Differences in TPMT activity between a control population and ALL 
patients 
 
 The TPMT activity in our patients with ALL at diagnosis is significantly lower 
compared with controls. This may be explained by a different age distribution of RBC 
in leukemic patients, containing a larger number of older cells compared with 
controls. After fractionating RBC, other authors have reported that human TPMT 
activity varied with RBC age, with mature RBC having a lower TPMT activity than 
younger cells.15 RBC of leukemic patients probably have a different age distribution, 
containing a larger number of older cells compared with the controls due to the 
inhibition or cessation of erythropoiesis by leukemic infiltration of the bone marrow. 
This earlier study of Lennard and colleagues also showed such a difference between 
TPMT activity at diagnosis in their patients with ALL compared with controls.15  They 
expressed TPMT activity as units per ml packed RBC. We used isolated RBC, 
expressing TPMT activity in pmoles per 107 viable RBC. 
 
 The differences in TPMT activity between controls and ALL patients at diagnosis 
cannot be explained by differences in the frequency of mutant alleles, because we 
found no higher prevalence of mutant alleles in the ALL group compared with 
controls, in concordance with results by McLeod and colleagues.13 This also gives a 
strong indication that children carrying TPMT mutations are not necessarily prone to 
leukemogenesis.  
 
  
The effect of RBC transfusions 
 
 During induction treatment, almost all patients with ALL receive (multiple) RBC 
transfusions. However, we did not observe any influence of RBC transfusions on the 
median TPMT activity in a subgroup of wild-type patients at diagnosis.  Nevertheless, 
we found an even higher TPMT activity after six weeks of treatment, compared with 
controls. So, it can be expected that the increase of TPMT activity is caused by 
therapy and cannot be attributed to RBC transfusions. It may even be that this rise in 
TPMT activity is underestimated, because of the mixture of patients’ RBC with donor 
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RBC, since the RBC TPMT activity in controls is lower than the activity in treated 
patients. 
 
 Prediction of the response of a patient to thiopurine treatment can be based either 
on measurement of TPMT activity or on mutational analysis or both. However, using 
the enzymatic activity measurements, TPMT deficiencies present at diagnosis or 
during treatment may be partly masked in individual cases, when these patients 
receive RBC transfusions from a donor with a high TPMT activity. An explicit example 
hereof has been described recently by Schwab and colleagues.29 Therefore, both 
measurement of TPMT activity and a mutational analysis are important to detect a 
TPMT deficiency. 
 
 
Conclusion 
 
 In conclusion, we found a lower TPMT activity in patients at presentation of ALL, 
when compared with controls. This difference in TPMT activity could not be explained 
by differences in the frequency of mutant alleles between controls and our ALL 
patients. Furthermore, it has been suggested previously that the increase of TPMT 
activity during ALL treatment could be ascribed to 6MP therapy. However, we 
demonstrated that TPMT activity is already increased before 6MP is administered. In 
vitro experiments indicated that this early increase could have been caused by the 
antifolates given during the induction treatment: i.e. intrathecal MTX and 
trimethoprim.  
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Abstract 
 
Inosine 5’-monophosphate dehydrogenase (IMPDH; EC1.1.1.205) catalyzes 
the rate-limiting step in guanine nucleotide biosynthesis, and may play an important 
role in treatment of patients with antipurines. 
 We used an HPLC method to measure the IMPDH activity in peripheral blood and 
bone marrow mononuclear cells (MNC). IMPDH activities were determined in 
children who were diagnosed with and treated for acute lymphoblastic leukemia 
(ALL), and in a group of control children.  
The median IMPDH activity for control children was 350 pmol/106 pMNC per hr 
(range 97-896; n=47). No gender or age differences were observed. IMPDH activity 
at diagnosis of ALL was correlated with the percentage of peripheral blood 
lymphoblasts (r=0.474; p<0.001; n=71). The median IMPDH activity at diagnosis was 
410 pmol/106 pMNC per hr (range 40-2009; n=76), significantly higher than for 
controls (p=0.012). IMPDH activity significantly decreased after induction treatment 
and during treatment with methotrexate infusions (median 174 pmol/106 pMNC per 
hr; range 52-516; n=21). The activity remained low during maintenance treatment 
with 6-mercaptopurine and methotrexate, at a significantly lower level than for 
controls (p<0.004). One year after cessation of treatment IMPDH activity has 
returned to normal values.   
 The decrease of IMPDH activity at remission of ALL seems to be at least partly 
due to the eradication of lymphoblasts with the type 2 isoform of the enzyme.  
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Introduction 
 
 Inosine monophosphate dehydrogenase (IMPDH) catalyzes the NAD+-dependent 
conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), 
which is the rate-limiting step in guanine nucleotide biosynthesis.1 During treatment 
with purine analogues, such as 6-mercaptopurine (6MP), the conversion of thio-IMP 
to thio-XMP by IMPDH is one of the crucial steps resulting in formation of thioguanine 
nucleotides (TGNs), which are incorporated into DNA and RNA, subsequently 
resulting in cytotoxicity. Hence, if a patient has a (very) low IMPDH activity in the 
malignant cells, treatment with thiopurines may be less effective in these cells. 
IMPDH activity may also provide an index for the efficacy of treatment of other 
diseases.2,3 Two isoforms of IMPDH have been described. Type 1 IMPDH is widely 
expressed, while type 2 IMPDH is induced during cellular proliferation and in some 
types of malignancy, e.g., in human leukemias, leading to a higher IMPDH activity.4-10 
We assessed the IMPDH activity of mononuclear cells (MNC) in peripheral blood and 
bone marrow of children presenting with ALL at diagnosis, and in peripheral blood 
during treatment of the disease and one year after cessation of therapy. We also 
assessed the pMNC-IMPDH activity in control children. 
 
 
Materials and methods 
 
Patients’ and control material 
 
Patients 
 Patients’ blood samples were obtained from 76 children with ALL included in 
the Dutch Childhood Oncology Group (DCOG), formerly the Dutch Childhood 
Leukemia Study Group (DCLSG) ALL-9 protocol, after written informed consent of 
the patients and/or their parents or guardians. The DCLSG-ALL-9-protocol included 
two risk groups: non-high-risk (NHR) and high-risk (HR).  HR criteria were: white 
blood cell count ≥ 50*109 /l, T-cell leukemia, broadened mediastinum, initial central 
nervous system or testicular involvement, presence of a t(9;22) or a bcr-abl-
rearrangement, presence of a t(4;11) or a 11q23 aberration with a mll- 
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rearrangement. Additionally, patients with mature B-cell-ALL were excluded. The 
DCLSG-ALL-9-NHR-protocol which was similar to the ALL-6 protocol,11 consisted of 
induction treatment (week 0-6) with vincristine, dexamethasone, L-asparaginase and 
triple intrathecal therapy, i.e. methotrexate (MTX)/cytosine-arabinoside/diadreson-F-
aquosum. After bone marrow remission, three weekly medium dose MTX infusions 
with intrathecal therapy (week 7-9) were administered. Treatment was continued by 
maintenance therapy (week 11-109), consisting of cycles of 7 weeks with 2 weeks 
vincristine and dexamethasone and 5 weeks of 6MP (50 mg/m2 per os daily) and 
MTX (30 mg/m2 per os weekly). Intrathecal treatment was administered once in 7 
weeks until week 60. 
 
With respect to this study, patients with HR-ALL were monitored until 
remission (week 6). The induction therapy of HR-ALL was similar to NHR-ALL with 
the addition of doxorubicin in the first 4 weeks.  
 
IMPDH activity of children with ALL was determined at diagnosis (week 0), 
after induction therapy (week 6), at the start of maintenance therapy (week 11), 
during maintenance therapy (weeks 25, 53, 81 and 109) and one year after cessation 
of treatment. During the period of maintenance treatment, blood was sampled within 
24 hours after a 5-weeks period of 6MP and MTX administration.  
 
 
Controls 
 As control material, heparinised blood was used from 47 children, after their 
written informed consent and/or after consent of their parents or guardians. These 
patients were non-critically ill children from the outpatient clinic of our department of 
Pediatrics at the University Medical Center Nijmegen. They were not suffering either 
from hematological, immunological or nephrological diseases, and also not treated 
with thiopurines. Validation experiments were performed with heparinised blood from 
a healthy donor. 
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Chemicals 
 
 IMP, XMP, NAD, Triton X-100, dithiotreitol (DTT) and tetrabutylammonium 
hydrogen sulphate (TBAS) were obtained from Sigma (St Louis, MO, USA). HPLC-
grade methanol was obtained from Labscan (Co. Dublin, Ireland). Dipotassium 
hydrogenphosphate, potassium dihydrogenphosphate and potassium chloride were 
obtained from Merck (Darmstadt, Germany).  
 
 
Sample isolation 
 
 MNC were isolated within 24 hours after blood sampling and bone marrow 
aspiration using Ficoll Paque (density 1.077 g/ml, Amersham Pharmacia Biotech 
Benelux). After isolation, the MNC were washed twice with Phosphate Buffered 
Saline (PBS; Baker, Deventer, the Netherlands). Subsequently, the MNC were 
resuspended in PBS containing 4% Bovine Serum Albumin (BSA; Serological 
Proteins Inc., Kankakee, IL, USA). Cell counts were performed by an automated cell 
counter (Sysmex F520, Goffin Meyvis, Tiel, the Netherlands). Cell viability was 
determined with the trypan blue exclusion test. IMPDH determinations in the control 
and ALL population were performed with 300,000 viable MNC. The cells were frozen 
quickly at -80°C and freeze-dried before being assayed.  
 
 
IMPDH activity assay 
 
 The incubation mixture was based on the conditions described by Montero et 
al.2 and consisted of 40 mM potassium dihydrogenphosphate buffer with 66.7 mM 
KCl, 1.7 mM NAD+, 0.16 mM DTT and 0.16 mM IMP in a total volume of 120 µL. This 
mixture was added to a freeze-dried pellet of the required amount of MNC and 
incubated for two hours at 37°C. In contrast to the method of Montero et al.,2 the 
reaction was terminated with three volumes of ice cold methanol and the proteins 
were precipitated at -20°C for 30 min. After centrifugation (15,000 rpm, 5 min, -4ºC), 
the supernatant was frozen at -80°C and freeze-dried overnight. This freeze-dried 
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residue was dissolved in 200 µL of buffer A (described below). After a second 
centrifugation, 100 µL of the supernatant were injected onto the HPLC column, thus 
measuring half of the total amount of IMP and XMP. Cell and substrate blanks, which 
were treated by the same procedure steps as the samples, were included. Cell 
blanks were samples of incubation mixtures with substrate but without cells. 
Substrate blanks contained cells but no substrate. 
 
 
HPLC analysis 
 
 The HPLC system comprised an autosampler (SP8880, SpectraPhysics, San 
Jose CA, USA), gradient HPLC pump (SP8800, Spectra Physics, San Jose CA, 
USA) and UV detector (759A, Applied Biosystems, Foster City, USA). The HPLC 
column used was a Betabasic-18 (5 µm, 150*4.6 mm; Keystone Scientific, Inc. 
Bellefonte PA, USA). Results were reviewed using Waters Millennium Software. A 
two buffer gradient system was used with buffer A, consisting of 40 mM potassium 
phosphate buffer containing 1.7 g/L TBAS, pH 3.0, and buffer B, consisting of 2 mM 
potassium phosphate buffer and 1.7 g/L TBAS (pH 3.0) with 65% methanol. Elution 
was performed with a 12 min linear gradient from 100% buffer A to 92.5% buffer A 
and 7.5% buffer B and elution continued on this level for three minutes. The system 
then returned to starting conditions in three minutes. Equilibration delay was twelve 
minutes. The flow was 1 mL/min. The assay product, XMP, was well separated from 
the substrate IMP. To optimise the reproducibility of the retention times, the HPLC 
column was flushed with 50% methanol after each sample set. IMPDH activity was 
calculated as pmoles of XMP formed per million viable MNC per hour of incubation. 
 
 
Statistics 
 
 The non-parametric Wilcoxon W test was used to compare IMPDH activities in 
the control population and the patients with ALL at diagnosis, and also to compare 
the IMPDH activities in male and female children. The Wilcoxon W test was also 
used to compare IMPDH activities in the controls and patients who were treated for 
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ALL or had terminated treatment for one year, and also to calculate the difference in 
initial IMPDH activity as well as the blast percentage in both ALL risk groups. 
Differences of patients’ IMPDH activity before, during and after ALL treatment were 
calculated by means of the Wilcoxon Signed Rank Test. The Spearman correlation of 
age with IMPDH activity was established in the control population. The percentages 
of lymphoblasts in the peripheral blood at the time of diagnosis of ALL patients were 
correlated with IMPDH activity by Spearman correlation.  
 
 
 
Results 
 
IMPDH activities in controls and children with ALL 
 
 The control group consisted of 47 children and young adults, aging from 1 to 
19 years, with a mean of 9.9 ± 5.2 years. The median IMPDH activity for the control 
group was 350 pmol/106 pMNC per hr (range: 97-896), as shown in Table 1. Activity 
did not vary by sex: in males (n=23) and females (n=24), the median IMPDH 
activities were 336 (range 97-835) and 354 (range 112-896) pmol/106 pMNC per hr, 
respectively (p = 0.8). We observed no correlation of IMPDH activity with age (r = 
0.067).  
 
 Table 1 shows the IMPDH activities obtained from 76 children with ALL at 
presentation. The ages ranged from 1 to 16 years with a mean of 5.7 ± 4.0 years, 
66% were male. At presentation of ALL, the median IMPDH activity in peripheral 
blood was 410 pmol/106 pMNC per hr (range 40-2009), which was significantly higher 
than the activity found in control children (p = 0.012). The IMPDH activities at 
diagnosis were positively correlated with the percentages of lymphoblasts in 
peripheral blood of 71 patients (range 0-94%; r = 0.474; p < 0.001; see Figure 1).  
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Figure 1. Scatter diagram of the relation between percentages of peripheral blood lymphoblasts at 
diagnosis and pMNC-IMPDH activity. Data are presented from 47 NHR and 24 HR patients. IMPDH 
activity is given in pmol/106 MNC per hr. The Spearman correlation is 0.474 (p<0.001). 
 
 
This correlation has been made for all but 5 patients, since not all lymphoblast 
percentages for both peripheral blood and bone marrow were successfully collected. 
In accordance with the definition of HR, the percentage of lymphoblasts in peripheral 
blood in HR patients (85 ± 11%; n = 24) was significantly higher, compared to NHR 
patients (percentage of lymphoblasts: 36 ± 27%; n = 47; p < 0.001). IMPDH activity of 
HR patients was significantly higher compared to that of NHR patients (p = 0.008). 
IMPDH activity in peripheral blood of NHR patients at diagnosis was similar to control 
values (p=0.187).  
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Table 1. IMPDH activity (expressed as pmol/106 MNC*hr) in control children and children presenting with ALL. Relevant significant differences are flagged: 
*compared to controls: p=0.012; **compared to controls: p<0.001; † compared to NHR in peripheral blood: p=0.008. 
 
IMPDH activity 
    median range  N    median range  N 
In peripheral blood:          In bone marrow: 
Reference   350  97-896  47 
Diagnosis ALL 
Total group   410*  40-2009 76    478  49-1321 49 
- stratified by risk group: 
NHR   384  40-1105 49    488  49-1200 29 
HR   489**†  197-2009 27    415  104-1321 20 
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The IMPDH activities in the bone marrow (see Table 1) were similar at 
diagnosis in both risk groups (p=0.382), as were the blast percentages: 88 ± 13% in 
the NHR group (range 38-98; n=47) vs. 91 ± 6% in the HR group (range 74-96; n=24; 
p=0.836). 
 
Figure 2. pMNC-IMPDH activity in children with NHR-ALL. IMPDH activity is given in pmol/106 MNC 
per hr. Values of patients with NHR-ALL are given at diagnosis (week 0; n=49), after induction 
treatment (week 6; n=24), after prophylactic treatment of the central nervous system (week 11; n=21), 
during maintenance treatment (week 25 (n=26), 53 (n=12), 81 (n=13), 109 (n=17)) and one year after 
cessation of treatment (n=8). The median IMPDH activity is marked by the horizontal line, the dots 
show the individual values. Control values were 350 (range 97-896) pmol/106 MNC per hr. 
 
  
Figure 2 shows the course of IMDPH activity in peripheral blood of NHR 
patients, from diagnosis until one year after cessation of treatment. IMPDH activity 
significantly decreased after induction treatment (week 6; median 247 pmol/106 
pMNC per hr; range 65-847; n = 32; p = 0.020 compared to diagnosis). At the start of 
maintenance treatment (week 11), after prophylactic treatment of the central nervous 
system with a medium dose MTX, IMPDH activity was significantly lower than at  
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week 6 (median 203 pmol/106 pMNC per hr; range 52-516, n = 22; p = 0.018), and 
compared to controls (p = 0.007). During maintenance treatment, until the end of 
treatment, IMPDH activity remained relatively unchanged (week 109: median 172 
pmol/106 pMNC per hr; range 57-374, n = 17; p = 0.066). One year after cessation of 
treatment, all patients evaluated showed a rise in IMPDH activity. The median 
IMPDH activity of these patients was 265 pmol/106 pMNC per hr (range 161-432; n = 
6), which is significantly higher than the median IMPDH activity determined during 
maintenance treatment (p = 0.028), and was not significantly different from controls 
(p = 0.075).  
 
 
Discussion 
 
 We observed a high IMPDH activity in the presence of malignant leukemic 
cells of patients with ALL. The median pMNC-IMPDH activity of all children 
diagnosed with ALL was higher than for controls. Furthermore, the IMPDH activity in 
bone marrow of NHR and HR patients, containing 88% and 91% blasts, respectively, 
at diagnosis was significantly higher compared to IMPDH activity in pMNC of controls 
(see Table 1). At diagnosis, the pMNC-IMPDH activities were positively correlated 
with the percentages of lymphoblasts in peripheral blood, and pMNC-IMPDH activity 
of HR patients with a high percentage of lymphoblasts, was higher than in NHR 
patients with a low percentage of blasts (see Figure 1 and Table 1). These data 
confirm the data of Price et al.12 and of Becher and Löhr,13 who demonstrated that 
IMPDH activity was dependent from the blast cell count. The lymphoblasts contain 
the inducible isoform, IMPDH type 2, whereas IMPDH type 1 is the predominant 
isoform in normal, resting lymphocytes.6 Thus, the raised level of IMPDH observed in 
ALL at diagnosis, may be attributed to lymphoblastic IMPDH type 2. This makes 
lymphoblasts more sensitive for treatment with 6MP than ¨normal¨ lymphocytes. In 
monitoring the effect of therapy, it could be of importance to follow the expression of 
type 2 IMPDH gene. This issue can be further addressed on the RNA level. 
 
 Although patients with HR-ALL demonstrated a significantly higher IMPDH 
activity, compared to controls due to the high percentage (85%) of lymphoblasts with 
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the type 2 isoform, patients with NHR-ALL (36% blasts) did not differ significantly 
from controls. We hypothesize this is due to the presence of larger numbers of  
¨normal¨ lymphocytes in case of NHR-ALL. In the combined patient group 
(HR+NHR), a significantly lower IMPDH activity is observed after eradication of type 
2 IMPDH blasts at remission (i.e. week 6) compared to IMPDH activity in controls. 
This may be due to either disease-related or therapy-related down-regulated type 1 
activity of IMPDH or both, resulting in a clinical lymphocyte dysfunction.14-17 
Hedstrom described, for example, that thio-IMP is an irreversible inactivator of 
IMPDH.18 The down-regulation of type 1 activity in ¨normal¨ lymphocytes may also be 
a salvage phenomenon for 6MP toxicity.  
 
At the time-point of one year after cessation of antileukemic therapy, the 
IMPDH activity has returned to control levels. During this period, restoration of 
lymphocyte function has been observed by other authors.14-17 
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Abstract 
 
 Thiopurines are used for treatment of several diseases. Cytotoxicity is caused by 
the derived compounds 6-thioguanine nucleotides (TGNs) and methyl-6-thioinosine 
monophosphate (methylthio-IMP). The 6-thiopurine mononucleotides 6-thio-IMP 
(thio-IMP), 6-thio-GMP (thio-GMP) and methylthio-IMP can be catabolized by purine 
5’-nucleotidase (5’NT). It has been shown that various 5’-nucleotidases are key 
enzymes for (6-thio)-purine metabolism. We aimed to investigate whether the overall 
5’NT activity is correlated with the efficacy and toxicity of 6-thiopurine nucleotides. 
 Substrate affinity of 5’NT for IMP, GMP, AMP, thio-IMP, thio-GMP and methylthio-
IMP was studied in human lymphocytes. For each of the substrates, the pH for 
optimal overall enzyme activity has been determined at a pH range between 6 and 
10. At the optimal pH, assays were performed to establish Km and Vmax values.  
 Optimal pH values for the various substrates were between 7 and 8.5. Km values 
ranged from 33 to 109 µM, Vmax ranged from 3.99 to 19.5 nmol/106 peripheral 
mononuclear cells (pMNC) per hr and Vmax/Km ratios ranged from 105 to 250.  
The results did not show a distinct preference of 5’NT activity for any of the tested 
thiopurine nucleotides. 
The enzyme kinetic studies furthermore revealed substrate inhibition by thio-IMP and 
thio-GMP as a substrate. Inhibition by thio-GMP also seems to occur in patients 
treated with 6-mercaptopurine, subsequently this may lead to toxicity in these 
patients. 
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Introduction 
 
 Thiopurines have been used since 1953 to treat a wide range of diseases. 
Azathioprine (AZA) is given to patients suffering from inflammatory and autoimmune 
diseases, but also in organ transplant recipients. AZA is the nitroimidazole derivative 
of 6-mercaptopurine (6MP), a hypoxanthine analogue, which is used in treatment of 
children with acute lymphoblastic leukemia (ALL). Metabolic activation of 6MP occurs 
by conversion into thio-IMP. This reaction is catalysed by hypoxanthine guanine 
phosphoribosyl transferase (HGPRT) and needs phosphoribosyl pyrophosphate 
(PRPP) as a cosubstrate. Thio-IMP can be converted into the TGNs which are 
incorporated into DNA and RNA to cause cytotoxicity. A second cytotoxic pathway is 
the methylation of thio-IMP to methylthio-IMP by thiopurine methyltransferase 
(TPMT).1 Methylthio-IMP has been shown to inhibit the purine de novo synthesis.2 
Methylation of 6MP to methyl-6MP is part of its catabolic pathway, a reaction which is 
also catalysed by TPMT. 
 
Deficiency of TPMT has been shown to induce hematological toxicity in 
patients suffering from leukemia or rheumatological diseases.3-5 Kerstens et al. 
showed a normal TPMT activity in some cases of hematological toxicity after 
azathioprine administration in rheumatological patients; these patients exhibited a 
deficiency of 5’NT.6 
 
 The family of 5’-nucleotidases (5’NTs) is constituted by various members, 
present in the cytoplasm (CNI, CNIA, CNIII, dNT1), in the mitochondria (dCNII), or 
membrane-bound (ecto-5’-nucleotidase or CD73+).7-12 The various forms catalyse 
the degradation step from monophosphorylated nucleosides to nucleosides. 
Endogenous purine substrates for purine 5’NTs are GMP, IMP and AMP. The 
thiopurine nucleotides thio-GMP, thio-IMP and methylthio-IMP are also converted by 
purine 5’NTs. We have studied the enzyme kinetic behaviour of total purine 5’NT for 
the various (thio)purine substrates, to elucidate whether - in patients treated with 
6MP -decreased overall 5’NT activity is correlated with increased thiopurine 
nucleotide concentrations.  
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Materials and methods 
 
Patients 
 
 Patients’ blood samples were obtained from children (aged 6.4 ± 4.3 years) 
with ALL included in the DCOG, formerly the Dutch Childhood Leukemia Study 
Group (DCLSG)-ALL-9 protocol after written informed consent of the patients and/or 
their parents or guardians. This protocol excluded patients with mature B-ALL. 
Patients were stratified into two treatment regimens: non-high-risk (NHR) and high-
risk (HR). Criteria for HR were: WBC count > 50*109/l, T-cell leukemia, broadened 
mediastinum, initial central nervous system or testicular involvement, presence of a 
t(9;22) or a bcr-abl rearrangement, presence of a t(4;11) or a 11q23 aberration with 
an mll rearrangement. Patients who did not meet any of these criteria at diagnosis 
were treated according to the NHR protocol, which is similar to the DCLSG-ALL-6 
protocol13 with the exception of triple intrathecal therapy in ALL-9, and four 
intravenous Paronal® (L-asparaginase) infusions in stead of 14 Crasnitin® (L-
asparaginase) infusions in ALL-6. Maintenance treatment consisted of alternating 
cycles of 2 weeks vincristine and dexamethasone, and 5 weeks of oral 6MP (50 
mg/m2 daily) and oral methotrexate (30 mg/m2 weekly) until week 109. 
 
5’NT activity was determined in children with NHR-ALL at diagnosis (week 0), 
and during maintenance therapy (week 25). During maintenance treatment, blood 
was sampled after a 5-week period of 6MP and MTX administration.  
 
 
Materials 
 
 Kinetic experiments were performed to establish the overall 5’NT activity. For 
this purpose, pMNC from a healthy donor were used. Patients’ blood samples were 
obtained from children with ALL included in the DCLSG-ALL-9 protocol. In these 
blood samples, 5’NT activity was determined in pMNC. In a subgroup of 16 patients, 
pMNC thio-GMP was measured during maintenance treatment.  
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 Before isolation of the blood cells, dithiotreitol (DTT; 5 mg/ml) was added to 
the peripheral blood. pMNC were isolated by Ficoll Isopaque (density 1.077 g/ml, 
Nycomed Pharma AS, Oslo, Norway). The interphase containing pMNC was washed 
twice in phosphate-buffered saline (PBS; NPBI, Emmer-Compascuum, the 
Netherlands). The pellet was dissolved in PBS containing 4% Bovine Serum Albumin 
(BSA; Sigma, St. Louis, MA, USA). The cells were counted by an automated cell 
Coulter counter. Cell viability was determined with the trypan blue exclusion test. For 
each determination concerning the kinetic experiments 50,000 freeze-dried pMNC 
were used. Measurement of 5’NT activity in the patients’ material was performed in 
5,000 pMNC. Concentrations of thio-GMP were measured in 4*106 pMNC. Cells were 
frozen quickly at -80°C before being assayed.  
 
 
Chemicals 
 
 6-Methyl-MP, 6MP-riboside (6MPR), 6-methyl-MPR, thio-IMP, 6tG-riboside 
(6tGR), AMP, GMP, IMP, hypoxanthine, adenosine, inosine, guanosine, guanine, 
Tris-HCl, DTT and Triton X100 were obtained from Sigma (St. Louis, MA, USA). 6tG, 
6MP and perchloric acid (PCA) were purchased from Fluka (Buchs, Switzerland). ß-
Glycerolphosphate (ß-GP), MgCl2, KH2PO4, K2HPO4 were purchased from Merck 
(Darmstadt, Germany). Methanol was obtained from Labscan (Co. Dublin, Ireland). 
Thio-GMP standard was prepared by chemical conversion of tGR as described by 
Breter and Mertes,14 with some modifications. In short, 6tGR was mixed with 
triethylphosphate and phosphoroxytrichloride. The suspension was violently shaken 
overnight at 4ºC. After removing excess phosphoroxytrichloride, residual 6tGR and 
thio-GMP were precipitated by chloroform. Excess chloroform was removed with N2 
after washing. To prevent oxidation of the thio-GMP, DTT was added to the solution. 
The purity grade was higher than 90%. 6-Methylthio-IMP was prepared by 
methylation of thio-IMP, as described by Keuzenkamp-Jansen et al .15 An amount of 
0.026 mmol of thio-IMP was dissolved in 500 µl of 2 N ammonia; after addition of 5 µl 
of methyliodide (0.078 mmol) the mixture was immediately vortexed. After incubation 
at room temperature for two hours, the suspension was flushed with N2 to remove 
excess of ammonia, frozen at -80ºC and freeze-dried. The concentration of the 
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compounds was measured spectrophotometrically as described by Keuzenkamp-
Jansen et al.15 
 
 
Determination of pH optimum of 5’NT for the various substrates 
 
 Total purine 5’NT activity in pMNC of patients has been determined as 
described by Stolk et al.16 This method was adapted for the kinetic experiments. All 
incubation mixtures consisted of 161 mM Tris-HCl, 64 mM MgCl2 and 1.34 mM β-GP. 
The pH optimum was determined, using several incubations varying in pH from 6 to 
10 with intervals of 0.5. A final substrate concentration of 0.3 mM was used for the 
following substrates: AMP, IMP, GMP, thio-GMP, thio-IMP, methylthio-IMP. The 
activity measurements were based on total product formation:  
 
AMP   →  adenosine + inosine + hypoxanthine (+ Pi) 
GMP   →  guanosine + guanine (+Pi) 
IMP   →  inosine + hypoxanthine (+Pi) 
methylthio-IMP →  methyl-MPR (+Pi) 
thio-GMP  →  6tGR + 6tG (+Pi) 
thio-IMP  →  6MPR + 6MP (+Pi) 
 
Enzyme incubations were performed in triplicate with 50,000 freeze-dried 
pMNC in a total incubation volume of 40 µl. Substrate and cell blanks were included. 
After a 3-h incubation at 37ºC, the reaction was stopped by adding 4 µl of PCA (0.4 
M final concentration). The suspension was kept on ice for 10 min, centrifuged, and 
35 µl of the supernatant were neutralized with 0.4 M K2HPO4 and centrifuged. Twenty 
µl of the supernatant were injected onto HPLC.  
 
 
Determination of Km and Vmax values of 5’NT 
 
 Incubation buffers consisted of 161 mM Tris-HCl, 64 mM MgCl2 and 1.34 mM 
β-GP. The incubation buffers were adjusted to the optimal pH as established for each 
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substrate. Various substrate concentrations of AMP, IMP, GMP, thio-GMP, thio-IMP 
and methylthio-IMP were used, ranging from 1 µM to 0.6 mM. Substrate and cell 
blanks were included. The further procedure was the same as mentioned above. Vmax 
was expressed as nanomoles of the products formed per 106 pMNC per hour of 
incubation, Km as µM. 
 
 
Inhibition experiments of 5’NT activity by 6tG 
 
 Incubation mixtures consisted of 161 mM Tris, 64 mM MgCl2 and 1.34 mM β-
GP, and 24 µM thio-GMP; pH 8.0. Inhibition was tested in pMNC with final 
concentrations of 1 and 3 µM 6tG. These concentrations are in the same range as 
found in the in vitro experiments of 5’NT activity with thio-GMP as substrate. 
Substrate and cell blanks were included. The further procedure was the same as 
mentioned above. 
 
 
HPLC system for 5’NT analyses 
 
 Measurements of substrates and products were performed with an HPLC 
system, consisting of an autosampler (SP8880; Spectra Physics, San Jose CA, 
USA), a gradient HPLC pump (SP8800, Spectra Physics, San Jose CA, USA), and a 
UV detector (759A, Applied Biosystems, Foster City, USA). AMP, IMP and GMP and 
their metabolites were detected at wavelength 260 nm, whereas thio-IMP and its 
products 6MPR and 6MP were detected at 320 nm, thio-GMP and its metabolites 
6tGR and 6tG at 342 nm, and methylthio-IMP and metabolites methyl-6MPR and 
methyl-6MP at 290 nm.  
 
 An Alltima-C18 reversed-phase column (250x4.6 mm, particle size 5 µm; 
Alltech, Deerfield, IL, USA) was used to separate substrate and the various products 
formed. Elution was performed at a flow rate of 1.25 ml/min, with a two-buffer 
gradient. Buffer A consisted of 25 mM KPi, buffer B of 50 mM KPi + 25% methanol. 
The gradient used to analyse mixtures with substrates GMP, AMP, IMP, thio-GMP 
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and thio-IMP is given in Table 1. Separation of methylthio-IMP, methyl-6MPR and 
methyl-6MP was performed isocratically with 4 mM KPi + 20% methanol. The buffers 
were filtered through a 0.45 µm membrane filter prior to use. Results were reviewed 
by a Waters Millennium Datasystem. 5’NT activities were calculated from the amount 
of products formed and were expressed as nanomoles of the products formed per 
106 pMNC per hour of incubation.  
 
 
Enzyme kinetic calculations and statistics 
 
 Enzyme kinetics were established by plotting the V-S curves. Non-linear 
regression has been performed by Graph Pad Prism (Graph Pad Software Inc., San 
Diego CA, USA) for calculations of Km and Vmax values.  
 
 
Table 1. Elution scheme for HPLC analysis when AMP, IMP, GMP, thio-GMP and thio-IMP are used 
as substrates for 5’NT. Buffer A: 25 mM KPi; buffer B: 50 mM KPi + 25% methanol. Flow rate: 1.25  
ml/min. 
 
Time Buffer A (%) Buffer B (%) 
(minutes)   
0 98 2 
5 96 4 
10 70 30 
20 20 80 
24 20 80 
25 98 2 
35 98 2 
   
 
 
Measurement of intracellular thio-GMP concentrations in patients 
 
Intracellular thio-GMP was measured in pMNC extracts as described by 
Keuzenkamp-Jansen et al.15 Results were reviewed by a Waters Millennium 
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Datasystem. The pMNC thio-GMP concentration was expressed as picomoles per 
106 pMNC. The pMNC-thio-GMP concentrations have been correlated, using 
Spearman correlation, with 5’NT activity in the pMNC.  
 
 
Results 
 
pH optimum, Km and Vmax values of total purine 5’NT for the various 
substrates 
 
 At analysis of each incubation mixture, the total amount of the products formed 
plus the residual amount of substrate was found to be identical to the amount of 
substrate in a blank sample without cells. The pH optimum for the various substrates 
was measured between pH 6 to pH 10. The established pH optima were 7.0 for thio-
IMP, 7.5 for IMP and methylthio-IMP, 8.0 for thio-GMP and 8.5 for GMP and AMP, 
respectively. Km and Vmax values are shown in Table 2 for each substrate, as well as 
Vmax/Km ratios and correlation coefficients of V-S curves as calculated by Graph Pad 
Software.  
 
The Km values for the endogenous purines AMP, IMP and GMP were 
comparable, 60, 56 and 75 µM, respectively. The Vmax/Km ratios for IMP and AMP 
were the highest, 250 and 194 respectively, however in the same order of those of 
the other compounds. The Vmax/Km ratio of 5’NT for GMP, thio-GMP and thio-IMP 
were 120, 120 and 105, respectively. 
 
 
Vmax was about twice as high for GMP (9.08 nmol/106 pMNC per hr), 
compared to thio-IMP and thio-GMP (5.42 and 3.99 nmol/106 pMNC per hr, 
respectively). 5’NT appeared to have the lowest Km (33 µM) and Vmax for thio-GMP. 
However, the Vmax values measured for thio-GMP and thio-IMP are rather pseudo-
Vmax values because of the remarkable inhibition at higher substrate concentrations, 
as shown for thio-GMP in Figure 1a and for thio-IMP in Figure 1b.  
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Table 2. Vmax, Km, ratio Vmax/Km and correlation coefficients of V-S curves of 5’NT, using AMP, GMP, 
IMP, thio-GMP, thio-IMP and methylthio-IMP as a substrate. Vmax is given in nmol/106 pMNC per hr, 
Km is given in µM.  
 
Substrate Vmax Km Ratio Vmax/Km  Correlation  
 (95% C.I.) (95% C.I.)  coefficient 
     
AMP 11.6 60 194 0.888 
 (8.38-14.8) (1-118)   
     
IMP 14.1 56 250 0.949 
 (11.6-16.6) (21-92)   
     
GMP 9.08 75 120 0.890 
 (6.27-11.9) (0-151)   
     
methylthio-IMP 19.5 109 179 0.984 
 (16.4-22.5) (61-157)   
     
thio-IMP 5.42 52 105 0.995 
 (4.36-6.47) (30-73)   
     
thio-GMP 3.99 33 120 0.991 
 (1.58-6.41) (3-64)   
     
 
 
 
Effect of 6tG on total purine 5’NT activity 
 
 Addition of 1 and 3 µM 6tG to the incubation mixture with 24 µM thio-GMP as 
substrate did not result in a lower 5’NT activity at conversion of thio-GMP. So, no 
product inhibition is observed. Incubation of donor lymphocytes with 1 and 3 µM 6tG 
resulted in 5’NT activities of 1.90 ± 0.04 and 2.21 ± 0.27 nmol/106 pMNC per hr,  
respectively (n=6). 5’NT activity without addition of 6tG was 1.89 ± 0.04 nmol/106 
pMNC per hr. Feedback inhibition was not studied with 6tGR, since 5’NT inhibition 
was still present when all 6tGR was converted to 6tG (Figure 1a). So, it cannot be 
expected that tGR plays an important role in the inhibition of 5’NT. 
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Figure 1. The V-S curves with (a) thio-GMP and (b) thio-IMP as a substrate for 5’NT. 5’NT activity is 
given in nmol/106 pMNC per hour, thio-GMP and thio-IMP concentrations are expressed in µM.  
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Inhibition of total purine 5’NT by thio-GMP in vivo in patients with 
ALL 
 
 The median 5’NT activity of ALL patients at diagnosis is 11.4 nmol/106 pMNC 
per hr (range 2.2-104.1; n = 78). Of these 78 patients, 39 were also measured at 
week 25, where 6MP had been given during 14 weeks. In most of these patients (28 
of 39), the 5’NT activity decreased during 6MP treatment. The median activity was 
52% of the initial activity at diagnosis (range = 0.6-25.3 nmol/106 pMNC per hr; 
n=39).  
 
As the in vitro data clearly showed inhibition of 5’NT activity in pMNC by thio-
GMP, we investigated whether this 5’NT inhibition would also occur in vivo. We 
determined intracellular pMNC thio-GMP levels at week 25 in a random subgroup of 
patients (n=16). Thio-GMP levels of these patients ranged from 5.12 to 9.59 pmol 
thio-GMP/106 pMNC. From 12 of these patients also, 5’NT activity was measured 
and these activities were correlated with the thio-GMP levels. As can be seen in 
Figure 2, it is clear that there is a statistically significant negative correlation between 
thio-GMP levels and 5’NT activity (Spearman’s correlation -0.633; p=0.031). 
 
 
Figure 2. Scatter diagram of pMNC thio-GMP levels and total purine 5’NT activity after 14 weeks of 
6MP treatment. Spearman’s correlation coefficient is -0.622 (p=0.031). 5’NT activity is given in 
nmol/106 pMNC per hour, pMNC thio-GMP concentration is expressed in pmol/106 pMNC. 
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Discussion 
 
 In patients with low total purine 5’NT activity, treatment of patients with 
azathioprine or 6MP may result in accumulation of thionucleotides and 
methylthionucleotides. These (methyl)thionucleotides can induce the toxic side 
effects observed in 5’NT-deficient patients as described by Kerstens et al.6 The 
increased concentration of thio-GMP leads to a higher cytotoxicity of treatment, and 
in case of increased methylthio-IMP to a stronger inhibition of the purine de novo 
synthesis. A high purine 5’NT activity may have the opposite effect: less 
(methyl)thionucleotides are available to exert a toxic effect. Inhibition of 5’NT activity 
may well have implications for the hematological toxicity caused by 6MP.  
 
We performed in vitro substrate affinity assays and observed no major 
differences in total purine 5’NT substrate affinity between the endogenous purines 
(GMP, IMP, AMP) and thiopurines (thio-GMP, thio-IMP, methylthio-IMP). The Km 
values for the substrates thio-GMP and thio-IMP were in the same order of 
magnitude. So differences were presumably not biologically significant. Since the Km 
and Vmax values and Vmax/Km ratios for all substrates were comparable, it can be 
stated that there is no major difference in affinity of total purine 5’NT for the several 
substrates. 
  
At higher concentrations of thio-GMP, the catabolic pathway is inhibited in 
vitro, hence further phosphorylation of thio-GMP to di- and triphosphates will 
probably occur by preference, leading to an increased cytotoxicity of 6MP. The 
inhibition is caused by the substrate thio-GMP itself. Our in vitro data also indicated a 
substrate inhibition of 5’NT by thio-IMP.  
 
Involvement of the sulfur atom of the thiopurine mononucleotides in the 
formation of a non-reactive complex with purine 5’NT may be suggested as a cause 
of the inhibition, since no inhibition is observed with methylthio-IMP as substrate: the 
-SH group is methylated in methylthio-IMP, so it is not active as a free thiol group. 
Another indication for the effect of methylation of the SH-group forms the study 
described by Skladanowski et al,17 also suggesting that the methylated substrate 
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would be protected against formation of -SS-bonds with the enzyme protein. This can 
also be concluded from the study of Worku et al., as they described the existence of 
histidyl and cysteinyl residues being essential for the action of 5’NT.18 So we 
hypothesize that, using thiomononucleotides as a substrate, a relatively strong -SS- 
bond may be formed between the cysteinyl residue of the enzyme and the free thiol 
group of the thiosubstrate. This would prohibit the enzyme to return to its free stage 
and thus cause enzyme inhibition.  
 
Keuzenkamp-Jansen et al. identified increasing concentrations of methylthio-
IMP during four high-dose 6MP infusions in patients with ALL, measuring an amount 
of 40 pmol methylthio-IMP in 106 pMNC after the fourth high-dose 6MP infusion.19 As 
the mean volume of lymphocytes is 230 fl,20 the intracellular concentration of 
methylthio-IMP in these patients is 174 µM, which is a substantial amount (Km = 109 
µM). Also, an increase in plasma methyl-MPR is observed. Thus, under these 
conditions, it appears that purine 5’NT has an important role in the in vivo catabolism 
of methylthio-IMP. 
 
 The affinity of 5’NT for thio-GMP is high (low Km value); however at concentrations 
exceeding 24 µM, a strong substrate inhibition is observed (see Figure 1a). To 
examine whether this phenomenon might have implications in vivo, we performed 
thio-GMP measurements in pMNC of patients treated with 6MP for ALL. We found a 
statistically significant negative correlation between pMNC levels of thio-GMP and 
total purine 5’NT activity. The intracellular concentrations of thio-GMP ranged from 
5.12 to 9.59 pmol/106 pMNC, corresponding to intracellular thio-GMP concentrations 
ranging from 22 to 41 µM in the patients. So, in most cases, thio-GMP concentrations 
were sufficient to exert an inhibitory effect on purine 5’NT activity. The intracellular 
thio-IMP levels in patients treated with 6MP are too low for an additional inhibitive 
effect on purine 5’NT in vivo. 
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Conclusion 
 
 In conclusion, the in vitro experiments show that there is no major difference in 
affinity for total purine 5’NT between thio-IMP, thio-GMP and methylthio-IMP.  Thio-
GMP and thio-IMP concentrations above 24 µM and 190 µM, respectively, lead to a 
decreased purine 5’NT activity in vitro. The intracellular thio-GMP concentrations in 
vivo during 6MP treatment are high enough to exert an inhibitory effect on purine 
5’NT activity. This decrease of total purine 5’NT activity may lead to toxicity during 
thiopurine treatment.  
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General discussion 
 
The studies described in this thesis focus on the activities of three enzymes 
involved in the metabolism of the drug 6-mercaptopurine (6MP) in children with acute 
lymphoblastic leukemia (ALL). Our major finding was the increase of TPMT activity 
during ALL treatment. Earlier studies already showed that TPMT activity increased 
during maintenance treatment with 6MP.1,2 This was generally accepted to be due to 
the administration of 6MP, which is a substrate for TPMT. However, one study 
indicated that a high TPMT activity could have been present already before starting 
maintenance treatment, but no clear evidence was provided.3 We discovered that the 
TPMT activity was indeed already at a maximal level at the end of the induction 
therapy, hence before 6MP was administered to the patients. The increased TPMT 
activity was presumably caused by the administered antifolates methotrexate (MTX) 
and/or trimethoprim, as we showed by in vitro experiments.  
 
TPMT activity could be of importance with regard to the individualisation of 
treatment. A (very) low TPMT activity was clearly related to hematological toxicity, 
which might be fatal.4-9 TPMT-deficient patients experienced more frequent 
hospitalization, more platelet transfusions, and more inevitably omitted doses of 
chemotherapy.4,10,11 Evans et al. showed that almost 66% of the patients 
experiencing a dose-limiting hematological toxicity during thiopurine treatment, were 
TPMT-deficient or heterozygous; this is a six-fold higher prevalence compared to the 
10% frequency of these subgroups in the general population.10  
Additionally, there is evidence for an association between a low TPMT activity 
and long-term effects of 6MP chemotherapy. Thomsen et al. showed an increased 
cancer risk in ALL patients with a low TPMT activity after treatment with 6MP and 
other cytotoxic drugs.12 Relling et al. observed in such patients a higher incidence of 
brain tumours after 6MP treatment and administration of other cytostatics  in 
combination with cranial radiotherapy.13 On the other hand, treatment failure occurs 
more often if patients have a high TPMT activity and/or a low TGN concentration.14-19 
For patients with ALL, this may lead to a decrease of about 20% in five years disease 
free survival (DFS).14-16,18,19  
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Optimal individual treatment can be performed after establishing the patient’s 
TPMT genotype before starting thiopurine treatment.10, 20-25 Individualisation of 
thiopurine treatment can also be done using TPMT activity measurements or both. 
The question arises: “what is the preferable manner to predict thiopurine toxicity or 
efficacy before thiopurine treatment is started?” Genotyping and activity 
measurements both have their drawbacks. Although Relling et al. showed complete 
concordance between genotype and TPMT activity,4 these genotype/phenotype 
correlations do not always present with clear cut-off levels. We and other authors 
found an overlap in TPMT activity of wild-type and heterozygous individuals.10,26-28 
This overlap in TPMT activity could be caused by unknown mutations in patients 
classified as wild-types, which can be detected by sequencing the complete TPMT 
gene. This could be interesting: although the majority of TPMT mutations are 
TPMT*3A, TPMT*3C and TPMT*2 mutations, it is possible that there are patients 
who carry other inactivating mutations. However, to my view, sequencing will only be 
worthwhile, if the TPMT gene of patients with a low TPMT activity (e.g., below 5 pmol 
6MeMP/107 RBC per hr) is screened, as these patients are at higher risk for 
developing severe toxicity caused by thiopurines. 
 
Apart from this lack of clear cut-off levels for genotype/phenotype correlations, 
patients with very high TPMT activities may benefit only from TPMT phenotyping: 
they will not be noticed in case of TPMT genotyping, as they do not carry the known, 
inactivating, mutations. In our populations, we found eight (i.e. approximately 4%) of 
these individuals, who might be at higher relapse risk than individuals with a normal, 
intermediate or low TPMT activity. Schmiegelow et al. showed that TPMT activity was 
higher for patients who relapsed after cessation of therapy compared with those who 
stayed in remission.29 A major drawback from TPMT phenotyping is that in individual 
cases RBC transfusions may bias the patient’s TPMT activity, if the donor’s TPMT 
activity is clearly higher or lower compared to the patient’s TPMT activity. 
Determination of TPMT activity in pMNC could circumvent this problem. However for 
this assay many cells (two millions per measurement) are needed, which often 
cannot be collected during treatment due to the low WBC count in the treated patient. 
For a good prognosis in ALL, it is necessary to experience some grade of 
hematological toxicity: WBC counts should be low. At diagnosis, it may be easier to 
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obtain an adequate amount of pMNC. Also, monitoring of the TPMT gene in 
microarrays may contribute to individualisation of thiopurine treatment. 
 
The clinical relevance of TPMT genotype and phenotype for the patients 
included in this thesis should still be established by correlation with survival and 
toxicity of 6MP treatment. Correlation with toxicity was not included in this thesis, 
because toxicity of treatment was not recorded systematically. Additionally, it is too 
early to draw a conclusion on a correlation of the data with survival, because five 
years DFS could not yet be determined.  
 
In the published literature, we could not find any studies monitoring 5’NT 
activity during ALL treatment with 6MP. Our studies showed that total purine 5’NT 
activity was clearly inhibited in vitro and in vivo by thio-GMP, one of the 6MP 
metabolites. In 92% of our 6MP-treated patients, intracellular thio-GMP 
concentrations in the patients’ pMNC exceeded those causing strong inhibition of 
5’NT activity in vitro. So, the indication of the in vivo relevance of thio-GMP for 5’NT 
inhibition was obtained from our own observations in ALL patients. Furthermore, 
pMNC thio-GMP concentrations and 5’NT activity in the pMNCs were negatively 
correlated. The decrease of 5’NT activity may well have clinical relevance since more 
hematological toxicity is shown in patients with a low 5’NT activity.30 A low 5’NT 
activity may lead to an accumulation of active thionucleotides.  
 
We monitored IMPDH activity during ALL treatment and confirmed the findings 
of Price et al.31 showing that IMPDH activity at diagnosis was related to the number 
of lymphoblasts in peripheral blood of the patients with ALL. IMPDH activity 
decreased in patients with ALL during the first six weeks of treatment compared to 
that at diagnosis, following the eradication of lymphoblasts during the induction 
treatment. Whether this decrease and the further decrease during the rest of 
treatment is clinically relevant needs to be elucidated still.   
 
An important drawback of the methodology used, is that the enzyme activity 
measurements during treatment have not been performed in the actual target cell: 
the leukemic cell. This is inherent to the treatment, eradicating those leukemic cells. 
It is probable that leukemic cells behave different from non-leukemic cells, as is the 
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case for IMPDH: we found that IMPDH activity in lymphoblasts is higher compared to 
that in lymphocytes. Furthermore, the investigations described in this thesis were 
observational: it is not known yet, whether the differences in enzyme activities will 
have clinical relevance in terms of outcome of the disease. So, it is worthwhile to 
investigate whether the courses of IMPDH, 5’NT and TPMT activities have clinical 
relevance by establishing correlations between DFS and enzyme activities. If the 
differences in enzyme activities have clinical relevance in terms of outcome of the 
disease, this can be used to individualise therapy. It is also possible that relatively 
new, pharmacogenomic techniques like the microarray will provide new insights in 
6MP resistance or sensitivity profiles from a genetic point of view.  
 
Clearly, although 6MP has been used for a long time in antileukemic 
treatment, still many questions have to be answered to optimise the benefit of this 
drug. However, by the measurement of purine key enzyme and TPMT activities, we 
have gained more knowledge on 6MP metabolism in ALL treatment. This knowledge 
can be used for further investigations on individualisation of thiopurine treatment.  
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Summary 
 
 Acute lymphoblastic leukemia (ALL) is characterized by an uncontrolled 
proliferation of lymphoblasts, and is the most frequent form of childhood cancers. 
Treatment has made great progress during the last three decades. Currently, the 
tendency is to perform risk-adapted treatment to further increase survival and 
minimize (long term) toxicity. This could, among others, be achieved by elucidation of 
the drug metabolism in patients. This thesis aims to get more insight into the 
metabolism of the drug 6-mercaptopurine (6MP) in pediatric patients with ALL.  
 
 6MP is a hypoxanthine analogue, and is activated by endogenous purine enzymes 
(see figure on the fold-out page at the back of this thesis). In the conversion of 6MP 
to active metabolites, several enzymes play a role. This thesis describes the course 
of three key enzymes involved in 6MP metabolism during ALL treatment: inosine 
monophosphate dehydrogenase (IMPDH), 5’-nucleotidase (5’NT) and thiopurine S-
methyltransferase (TPMT). 
 
We have developed a method based on high-performance liquid 
chromatography for the measurement of TPMT activity (Chapter 2). During the 
performance of mutation analyses of the TPMT gene, we encountered some pitfalls, 
resulting from incomplete restriction endonuclease digestion. These pitfalls in 
genotype analyses are described in this thesis (Chapter 3). TPMT activities and 
genotypes have been determined in patients with ALL and in control children 
(Chapter 4). Median red blood cell (RBC) TPMT activity in ALL patients at diagnosis 
was significantly lower than in controls (median 11.5 pmol/107 RBC per hr; range 1.7-
30.7; n=191 vs. 14.6 pmol/107 RBC per hr; range 1.6-50.7; n=140). This reduction of 
TPMT activity in ALL patients was not due to differences in the frequency of 
mutations in the TPMT gene. In concordance with other authors, we found a higher 
TPMT activity during maintenance treatment with 6MP than at diagnosis and in 
controls. However, we observed that TPMT activity was already significantly 
increased to a maximal level after the induction therapy, before the patients received 
6MP (median 17.5; range 3.9-40.3 pmol/107 RBC per hr; n=139). In in vitro 
experiments, we showed that the early increase of TPMT activity during treatment 
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was presumably caused by the use of antifolates, e.g., methotrexate and 
trimethoprim.  
 
 Because IMPDH catalyzes the rate-limiting step in guanine nucleotide 
biosynthesis, and may play an important role in treatment of patients with antipurines, 
we monitored IMPDH activity during ALL treatment (Chapter 5). We confirmed 
previously described findings showing that IMPDH activity at diagnosis was related to 
the number of lymphoblasts in peripheral blood of the patients with ALL (r=0.474; 
p<0.001; n=71). The median IMPDH activity at diagnosis was 410 pmol/106 
peripheral mononuclear cells (pMNC) per hr (range 40-2009; n=76), significantly 
higher than for controls (350 pmol/106 pMNC per hr; range 97-896; n=47; p=0.012). 
IMPDH activity significantly decreased during induction treatment (to a median of 247 
pmol/106 pMNC per hr; range 65-874; n=32), compared to that at diagnosis, following 
the eradication of lymphoblasts, and during prophylactic central nervous treatment 
with methotrexate infusions (to a median of 203 pmol/106 pMNC per hr; range 52-
516; n=22). The activity remained low during maintenance treatment with 6MP and 
methotrexate, at a significantly lower level than for controls (median 172 pmol/106 
pMNC per hr; range 57-374; n=17; p<0.004). One year after cessation of treatment, 
IMPDH activity has returned to normal values.   
 
We studied total purine 5´NT activity in more detail (Chapter 6). We aimed to 
investigate whether total purine 5’NT activity was correlated with the efficacy and 
toxicity of 6-thiopurine nucleotides. Therefore, we studied substrate affinity of purine 
5’NT for IMP, GMP, AMP, thio-IMP, thio-GMP and methylthio-IMP in human 
lymphocytes. The results did not show a distinct preference of total purine 5’NT 
activity for any of the tested (thio)purine nucleotides. The enzyme kinetic studies 
furthermore revealed substrate inhibition by thio-IMP, and especially by thio-GMP as 
a substrate. Inhibition by thio-GMP also seems to occur in ALL patients during 
treatment with 6MP. Apart from the decrease of purine 5’NT activity during ALL 
treatment described above, we also showed a negative correlation between purine 
5’NT activity and thio-GMP concentration in patients’ pMNC. This may lead to 
hematological toxicity in thiopurine-treated patients. 
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So, by the measurement of purine key enzyme and TPMT activities, we have 
gained more knowledge on 6MP metabolism in ALL treatment. This knowledge can 
be used for further investigations on individualisation of thiopurine treatment in order 
to optimise efficacy and circumvent too much toxicity. 
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Samenvatting 
 
De meeste kinderen die kanker krijgen hebben acute lymfatische leukemie 
(ALL). ALL wordt gekenmerkt door een ongebreidelde celdeling van lymfoblasten, de 
kwaadaardige cellen. De laatste dertig jaar is de behandeling sterk verbeterd, maar 
nog niet optimaal. Tegenwoordig is de tendens om de behandeling meer op de 
individuele patiënt te richten om de effectiviteit van de behandeling en dus de 
overleving te verbeteren. Tevens wil men zoveel mogelijk de bijwerkingen vermijden.  
 
In Nederland wordt de behandeling van kinderen met leukemie gecoördineerd 
door de Stichting Kinderoncologie Nederland (SKION), voorheen de Stichting 
Nederlandse Werkgroep voor Leukemie bij Kinderen (SNWLK). Vanaf januari 1997 
tot oktober 2004 werden de kinderen met ALL behandeld volgens het SNWLK-ALL-9 
protocol. De kinderen die worden behandeld volgens dit protocol worden 
onderverdeeld in 2 groepen: een Hoog Risico (HR) groep en een Niet Hoog Risico 
(NHR) groep. De kinderen die bij diagnose bepaalde kenmerken vertonen waarvan 
bekend is dat ze een slechtere prognose geven, krijgen een zwaardere behandeling.  
 
De behandeling bestaat uit verschillende onderdelen. Gedurende de eerste 
zes weken dienen de bloedkankercellen, de lymfoblasten, te worden uitgeroeid. Dit 
deel wordt de inductiebehandeling genoemd. Vervolgens wordt specifiek het centrale 
zenuwstelsel aangepakt, omdat zich daarin nog lymfoblasten kunnen bevinden. De 
kinderen die in de HR-groep zitten, krijgen vervolgens een zogenaamde 
intensiveringsbehandeling. Er worden dan andere en extra medicijnen gegeven, ten 
opzichte van de NHR-groep. Het laatste en meest omvangrijke deel van de 
behandeling is de onderhoudstherapie. Die zorgt ervoor, dat de mogelijk toch nog 
aanwezige kwaadaardige cellen niet meer kunnen groeien, zodat langdurig herstel 
kan worden bewerkstelligd.  
 
Tijdens de onderhoudstherapie is 6-mercaptopurine (6MP) één van de 
toegediende medicijnen. Hoewel 6MP al zo’n 50 jaar wordt gebruikt voor de 
behandeling van leukemie, weet men nog steeds niet precies hoe de omzetting van 
deze stof, het metabolisme, precies verloopt in het lichaam. Als dit wel bekend zou 
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zijn, zou 6MP nog efficiënter kunnen worden toegepast, zodat de overleving 
misschien nog verbeterd kan worden.  
 
 
Wat is bekend over het 6MP metabolisme? 
 
 Op de uitklappagina achter in het proefschrift staat het schema van het 6MP-
metabolisme weergegeven. 6MP is zelf geen werkzame stof. Het wordt pas actief 
tegen de kwaadaardige cellen, de lymfoblasten, als het omgezet wordt door 
bepaalde enzymen. Een cruciale eerste stap is de omzetting van 6MP tot thio-IMP, 
door het enzym hypoxanthine-guanine fosforibosyltransferase (HGPRT). Vervolgens 
kan thio-IMP worden omgezet in twee andere stoffen die beiden effect hebben op 
lymfoblasten. Enerzijds kunnen door het enzym inosine monofosfaat dehydrogenase 
(IMPDH) de zogenaamde thioguanine nucleotiden (TGNs) worden gevormd. Deze 
TGNs worden ingebouwd in DNA en RNA, hetgeen resulteert in afsterving van cellen 
waarin dit proces plaatsvindt.  Anderzijds kan een ander enzym, thiopurine 
methyltransferase (TPMT), het thio-IMP omzetten tot methylthio-IMP, een stof die de 
purine de novo synthese kan remmen. Met name de kwaadaardige cellen zijn 
afhankelijk van de purine de novo synthese.  
 
Het TPMT enzym heeft eigenlijk een tweeledige functie: het zorgt niet alleen 
voor het (mede-)activeren van 6MP, maar ook voor het inactiveren ervan als 
bijvoorbeeld 6MP zelf wordt omgezet door TPMT. Een ander enzym dat de 
werkzaamheid van 6MP vermindert, is 5’-nucleotidase (5’NT). Van deze twee 
enzymen is aangetoond dat ze samenhangen met het aanslaan van de therapie. Een 
hoge activiteit van (één van) beide enzymen resulteert in een grotere kans op het 
terugkomen van de ziekte. Een lage activiteit daarentegen, kan resulteren in heftiger 
nevenreacties op de 6MP-behandeling. Voor de behandeling van ALL is het nodig 
om een bepaalde mate van hematologische toxiciteit (verlaagd aantal witte 
bloedcellen) na te streven, maar het kan ook zijn dat iemand te gevoelig reageert. 
Als vantevoren bekend is dat iemand heel gevoelig zal reageren op 6MP, dan 
zouden vervelende bijwerkingen voorkomen kunnen worden, zoals 
beenmergtoxiciteit die zelfs dodelijk kan zijn (in geval van een lage TPMT-activiteit).  
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Wat is de belangrijkste vraag voor dit proefschrift? 
 
De belangrijkste vraag die we ons hebben gesteld, is de volgende:  
 
Wat is het verloop van de activiteiten van de purine enzymen IMPDH en 5’NT, en 
TPMT gedurende de behandeling van kinderen met ALL? 
 
 
Hoe hebben we inzicht willen verkrijgen? 
 
Kinderen die ALL kregen in de periode oktober 1997 tot augustus 2000, zijn 
gevraagd mee te doen met het onderzoek dat in dit proefschrift wordt beschreven. 
Indien de patiënten (of hun ouders/voogden) toestemming verleenden, werden ze 
gevolgd vanaf de diagnose, gedurende de twee behandelingsjaren tot één jaar na 
het stoppen van de therapie. Op gezette tijdstippen gedurende deze periode werden 
bloedmonsters, en indien noodzakelijk voor diagnostische bepalingen, 
beenmergmonsters afgenomen. Voor dit onderzoek werden alleen bij diagnose 
analyses in beenmerg gedaan.  
 
 
Wat hebben we gevonden? 
 
 Na een nieuwe en snelle meetmethode te hebben ontwikkeld voor de meting 
van de activiteit van het enzym TPMT (zie hoofdstuk 2), zijn activiteitsbepalingen 
gedaan in kinderen met ALL en kinderen die geen ALL hadden (de contrôlegroep).   
Ook is er gekeken naar eventuele mutaties in het TPMT-gen. Tijdens de uitvoering 
van deze analyses kwamen enkele valkuilen aan het licht, die de uitslag van de 
analyses konden beïnvloeden. Deze valkuilen zijn beschreven in hoofdstuk 3.  In 
hoofdstuk 4 worden de uitslagen van activiteitsbepalingen en mutatie-analyses 
beschreven. Het bleek dat kinderen met ALL bij diagnose, dus voordat de 
behandeling begonnen was, een lagere TPMT-activiteit hadden dan de kinderen van 
de contrôlegroep (mediaan 11.5 pmol/107 RBC per uur; bereik 1.7-30.7; n=191 vs. 
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14.6 pmol/107 RBC per uur; bereik 1.6-50.7; n=140). Dit verschil kon niet worden 
verklaard door verschillen in vóórkomen van mutaties in het TPMT-gen. 
 
 Zoals andere onderzoekers ook hebben aangetoond, werd in dit onderzoek 
een hogere TPMT-activiteit gevonden tijdens de onderhoudsbehandeling met 6MP, 
vergeleken met een contrôlegroep en met de waarden die in de kinderen bij 
diagnose werden gevonden. Algemeen werd aangenomen dat dat kwam door de 
toediening van 6MP: het TPMT-enzym werd geactiveerd, omdat er meer substraat 
(in dit geval: 6MP) beschikbaar was. Echter, wat een nieuwe bevinding was, was dat 
de TPMT-activiteit al eerder tot een maximaal niveau verhoogd was, namelijk 
gedurende de inductiebehandeling, dus vóórdat de patiënten 6MP hadden gekregen 
(mediaan 17.5; bereik 3.9-40.3 pmol/107 RBC per uur; n=139). Met behulp van in 
vitro experimenten in het laboratorium kon door ons worden aangetoond dat de 
vroege stijging van TPMT-activiteit hoogstwaarschijnlijk werd veroorzaakt door een 
andere groep geneesmiddelen die de kinderen met ALL krijgen: de antifolaten 
trimethoprim en methotrexaat. De TPMT-activiteit bleef hoog gedurende de gehele 
ALL-behandeling.  Eén jaar na beëindigen van de behandeling waren de TPMT-
activiteiten gedaald tot contrôle waarden, wat eerdere bevindingen van andere 
auteurs bevestigt. 
 
 Omdat het enzym IMPDH een snelheidsbepalende stap in de vorming van 
TGNs vormt, en IMPDH een belangrijke rol kan spelen in de behandeling met 
bijvoorbeeld 6MP, is de IMPDH-activiteit gevolgd gedurende de ALL-behandeling 
(hoofdstuk 5). Eerder beschreven bevindingen werden bevestigd: IMPDH-actviteit bij 
diagnose is gerelateerd aan het aantal lymfoblasten in het bloed van patiënten met 
ALL (r=0.474; p<0.001; n=71). Bij diagnose was de mediane IMPDH-activiteit 410 
pmol/106 perifere mononucleaire cellen (pMNC) per uur (bereik 40-2009; n=76). Dit is 
significant hoger dan de waarden die zijn gemeten in de contrôlegroep (350 pmol/106 
pMNC per uur; bereik 97-896; n=47; p=0.012). Tijdens de inductiebehandeling 
daalde de IMPDH-activiteit significant vergeleken met de diagnose waarde tot een 
mediane waarde van 247 pmol/106 pMNC per uur; bereik 65-874; n=32). Dit hangt 
samen met het verdwijnen van de lymfoblasten. De activiteit daalde verder 
gedurende de periode van behandeling van het centrale zenuwstelsel (tot een 
mediaan van 203 pmol/106 pMNC per uur; bereik 52-516; n=22). De IMPDH-activiteit 
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bleef laag gedurende de onderhoudsbehandeling met 6MP en methotrexaat; 
gedurende deze fase was het niveau significant lager dan in de contrôles (mediaan 
172 pmol/106 pMNC per uur; bereik 57-374; n=17; p<0.004). Eén jaar na het 
beëindigen van de therapie was de IMPDH-activiteit weer terug op het normale 
niveau.   
 
In hoofdstuk 6 is onderzocht of purine 5’NT-activiteit gecorreleerd was met de 
effectiviteit en toxiciteit van 6-thiopurine nucleotiden. Om dit na te gaan, is in humane 
lymfocyten de affiniteit van purine 5’NT bestudeerd voor verschillende substraten: 
IMP, GMP, AMP, thio-IMP, thio-GMP and methylthio-IMP. De resultaten lieten geen 
duidelijke voorkeur zien van purine 5’NT voor één van deze stoffen. Opvallend was 
dat deze enzymkinetische studies een remming van de purine 5’NT activiteit lieten 
zien die veroorzaakt werd door het substraat. Dit gebeurde met thio-IMP als 
substraat, maar nog veel duidelijker indien thio-GMP als substraat werd gebruikt. 
Deze in vitro remming bleek tevens relevant voor patiënten met ALL tijdens 
behandeling met 6MP. Bij meting van thio-GMP concentraties in pMNC van 
patiënten, bleek een negatieve correlatie te bestaan tussen purine 5’NT-activiteit en 
de thio-GMP-concentratie. Dit kan leiden tot hematologische toxiciteit in patiënten die 
met 6MP (en andere thiopurines) worden behandeld.  
 
Samengevat: gedurende de behandeling van ALL-patiënten werden 
veranderingen gezien in purine 5’NT-, IMPDH- en TPMT-activiteit. Door middel van 
de bepalingen van de twee bovengenoemde purine enzym- en TPMT-activiteiten, 
hebben we meer kennis vergaard over het 6MP-metabolisme tijdens de ALL-
behandeling. Deze kennis kan worden gebruikt voor verder onderzoek op het gebied 
van de individualisering van thiopurine behandeling om effectiviteit te optimaliseren 
en bijwerkingen zoveel mogelijk te vermijden. 
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Dankwoord 
 
Het boekje is dan toch eindelijk klaar. Dat het zover gekomen, is te danken 
aan veel mensen: onderzoek is echt teamwork! Ik moet talloze mensen bedanken die 
op zoveel verschillende niveaus hun bijdrage hebben geleverd.  
 
Mijn promotores Frans Trijbels en Peter Hoogerbrugge. 
Beste Frans, je bent al zoveel geprezen vanwege je consciëntieuze manier van 
nakijken van manuscripten: ik wil daar zeker niet bij achterblijven. Je dacht altijd 
mee, en je deur stond altijd open als het nodig was. Je hebt veel energie moeten 
steken in het rondbreien van dit boekje, zelfs tijdens je vakanties. Hartelijk bedankt! 
Beste Peter,  je bent er pas in een later stadium bijgekomen. Hoewel het nakijken 
van manuscripten vaak niet zo snel ging als bij Frans, heb je wel het onderzoek op 
een cruciaal moment uit een impasse weten te halen. Ook voor je frisse en kritische 
kijk op onze bevindingen wil ik je bedanken.  
 
Mijn copromotores Ronney De Abreu en Jos Bökkerink. 
Beste Ronney, ik heb niet de maandagavonden geteld die jij voor mij hebt opgeofferd 
om te discussiëren over de verschillende hoofdstukken in het proefschrift, maar ze 
zijn zeker niet meer op 2 paar handen te tellen. Ik waardeer het zeer, dat jij zo 
duidelijk mijn promotie als een missie had uitgeroepen. Ik wil je inderdaad graag op 
een voetstuk plaatsen, want als jij er niet was geweest, was dit boekje er ook niet 
geweest, en geloof me, dat zegt heel veel! Jij gaf me vertrouwen, erg veel steun, en 
zo de kracht om door te gaan.  
Beste Jos, het zal je ongetwijfeld moeilijk gevallen zijn om door te gaan. Je hebt toch 
nog de moeite op kunnen brengen om de manuscripten na te kijken. Bedankt.  
 
Mijn paranimfen en mijn andere HPLC-labgenoten. 
Lieve Jenneke en Lambert, jullie hebben al zoveel goede diensten verleend door de 
jaren heen, zonder ooit als paranimfen naast de promovendus te hebben gestaan, 
vandaar dat jullie nu welzeker die rol moesten vervullen. En natuurlijk ook, omdat 
jullie ook belangrijk zijn geweest voor dit onderzoek. Ik kon altijd bij jullie terecht, of 
het nou om onderzoeksgerelateerde zaken ging, of om persoonlijke 
beslommeringen.  
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Bovenstaande woorden gelden ook voor de mensen die de rol van paranimf ook 
zeker hebben verdiend, maar niet in die rol geplaatst konden worden omdat de Pedel 
zoveel paranimfen teveel vond: Patricia ter Riet, Karina Horsting-Wethly, Trude 
Vogels-Mentink, Anke van Dijk en Anneke Stegeman. 
Lieve Patricia, als ik aan jou denk, denk ik altijd aan panda’s, rara, hoe kan dat? Ik 
denk dan ook aan loyaliteit, en heel veel moeite doen om analyses aan de gang te 
krijgen. Het heeft ons menige zweetdruppel en frustratie gekost, maar het is ons toch 
gelukt: het boekje ligt nu in onze handen.  
Lieve Karina, jij was altijd zo heerlijk direct. En echt crea-bea, niet alleen met 
handwerkdingen, maar ook met labzaken. Ik hoop dat je altijd met veel plezier zult 
blijven werken, en ik hoop ook vooral dat je nog heel veel plezier zult beleven aan 
David en Levi, en natuurlijk Bert.  
Lieve Trude, jij hebt ook je bijdrage aan meerdere onderzoeken mogen geven, en dat 
heb je altijd met veel plezier gedaan. Je hebt je ook altijd heel consciëntieus ingezet 
voor onze gezamenlijke klusjes: het is een puik stukje werk! 
Lieve Anke, ik heb je maar even mee mogen maken, maar je wist je al verdienstelijk 
te maken voor dit onderzoek, dankzij je leergierige attitude: houden zo, meid! 
Lieve Anneke, hoewel je nu al lang niet meer in het HPLC-lab woonachtig bent, kan 
ik het niet nalaten jou ook in een adem mee te noemen met de bovengenoemden, 
want voordat je naar het spierlab ging, heb je toch ook menig klusje verricht voor dit 
project! 
Ik wil jullie allemaal bedanken voor de heel goede tijd die ik op het HPLC-lab heb 
gekend.  
 
Maar het lab was groter: ik wil iedereen van het hele lab bedanken, voor het 
meeleven met ieders promotieperikelen. In het bijzonder wil ik Maroeska Crommert- 
te Loo bedanken, die altijd haar drukke werkzaamheden aan de kant kon zetten voor 
een verhelderend of opluchtend kopje thee. Ik denk ook nog vaak aan onze voor 
andere mensen soms schokkende woordenwisselingen: heerlijk! Ik gun jou, Jeroen 
en julle dochter Sofie alleen maar het beste van de wereld: dat hebben jullie dik 
verdiend! 
Ook wil ik speciaal Irma Versleyen-Loe bedanken. Irma, ik hoop dat we elkaar nog 
regelmatig mogen zien, en dat ik Stef weer eens mee mag nemen om te vogelen.  
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En dan Frans Zegers! Frans is echt de gouden kracht die elk lab zou moeten 
hebben; altijd heel erg bereid om al zijn belangrijke klusjes te doen. Voor mij 
betekende dat, dat de patiëntenmonsters steeds zorgvuldig werden getransporteerd 
van Den Haag naar Nijmegen. Frans, bedankt voor je tomeloze inzet! 
Wat ik erg leuk vond, was het begeleiden van studenten.  
Kai Ament, jij hebt je stageperiode gevuld met de opzet van de TPMT-genotyperings 
assays. Dat is goed gegaan, want delen van jouw verslag zijn verwerkt in één de 
artikelen. Je bent inmiddels zelf bezig met een AiO-baan: heel veel succes en 
bedankt voor je werk op ons lab! 
Inge Zonnenberg, mijn enige ‘klinische’ student. Jij hebt je met veel enthousiasme 
gekweten van je stagetaak. Het leven gaat door en ook jij bent goed terecht 
gekomen: je werkt nu als arts. Ik weet zeker dat je een plezierige arts en collega 
bent. Bedankt voor je inzet. 
Jori van Geffen, lekkere kwebbelaar. Het was wel stil hoor, toen jouw stageperiode 
erop zat. Je hebt veel moeite gestoken in het opzetten van een geschikte 
analysemethode voor methotrexaatpolyglutamaten. Dat het niet bleek te werken, was 
natuurlijk erg jammer, maar: geen resultaat is ook resultaat! Je hebt niet het hoofd 
laten hangen, je was altijd opgewekt. Ik heb nog even voor je leven gevreesd toen je 
een blind date had met een internet-deerne, maar gelukkig is ook dat allemaal goed 
gekomen. Heel veel geluk in je leven, enneh: is die scriptie inmiddels af?  
En dan de stap- en feestactiviteiten met de andere promovendi ‘van die tijd’: ik 
heb er altijd erg van genoten. Ik hoop voor jullie allemaal het allerbeste! (en dat geldt 
natuurlijk voor alle mensen van het lab K+N!) 
 
Het leven was ook druk naast het Nijmeegse lab. Want waar de mensen het 
ook heel druk hadden met dit onderzoek, was in Den Haag, bij de SNWLK. Laat 
niemand uitpoetsen wat ze daar aan bloedmonsters hebben moeten opwerken voor  
ons! Want: de mensen van het SNWLK-lab hebben meer dan 1250 keer 
bloedmonsters opgewerkt, wat betekent dat ze zo’n 40 duizend epjes hebben gevuld! 
Corné en Birgit: hartelijk bedankt voor de coördinatie op jullie lab. En Fransje, 
bedankt voor de uitgebreide overzichten die wij nodig hadden om de labgegevens te 
kunnen evalueren. Maar ook alle anderen van de SNWLK: hartelijk bedankt voor het 
mogelijk maken van de uitvoering van dit grootschalige project.  
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 Alle mensen die het materiaal verwerken, zijn natuurlijk belangrijk, maar óók 
de mensen die zorgen dat er materiaal beschikbaar wordt gesteld: de kinderartsen in 
Nederland, én de patiënten en hun ouders of voogden. Hartelijk bedankt! 
 Verder wil ik ook de werkbesprekingen memoreren met de afdeling ‘Genetic 
metabolic diseases’ van het AMC: Albert, Andre, Jörgen, Rutger en de anderen. 
Bedankt voor de fijne discussies en heel veel succes allemaal! 
  And then Jacob Selhub and Joel Mason. I will never forget my (short) time in 
Boston, at your lab. It is a pity I could not get the method to work back in Nijmegen, 
with the low concentrations of methotrexate polyglutamates in our material. But I did 
learn some important lessons about life. Thanks for that! 
 
Ik heb een hele lijst gehad. Het zijn allemaal mensen die met de uitvoering van 
het project te maken hadden, en/of min of meer directe collega’s waren. Er was 
echter ook leven naast het onderzoek. Mijn vrienden, erg belangrijk voor de mentale 
ondersteuning en de afleiding. Al heb ik veel van mijn vrienden niet zo vaak gezien 
als ik gewild had. Ik wil degenen bedanken die zo geduldig zijn geweest, dat ze nog 
steeds mijn vrienden willen zijn.  
De skûtsjesilers: Jitze & Hiske, Karin & Jan, Siegfried & Antje. Ik ken jullie al zolang, 
en we hebben nog steeds contact. We hebben dan ook een bijzondere band, het 
skûtsjesilen, ‘yn’e tiid dat it noch wis moai sile en gesellich wie’. En Karin, er is weer 
een mooi werkstuk van je vereeuwigd, in de omslag van dit boekwerk: heel erg 
hartelijk bedankt voor je bijdrage, die je tussen je eigen promotie- en 
moederwerkzaamheden door hebt moeten klaarspelen. Je bent fantastisch!  
Mijn oude middelbare schoolvrienden: Marco, Janynke, Hilde, Marianne, Loek. Het is 
altijd zo heerlijk om jullie te zien, het is een band die niet te verbreken is. Want in de 
loop van de tijd is wel gebleken: al hebben we elkaar een tijd(je) niet gezien, we 
vinden elkaar altijd weer.  
Mijn Groningse tijd: Monique, Margje, Wendy. Het wordt hoog tijd dat wij elkaar ook 
weer eens (vaker) gaan zien.  
De Wageningse voedingsmiepen: Annekatrien, Frieda, Lybrich, Wik, Evelien, Ingrid, 
Margriet, Ellen, Saskia. Onze gezamenlijke activiteiten zijn altijd erg leuk. De laatste 
tijd komt het vaak neer op trouwpartijen en kraamvisites, maar ja, dat zal wel aan 
onze leeftijd liggen. Een andere Wageninger heeft ook heel geduldig moeten 
afwachten, en dat is Wouter:  ‘Hald dy fêst, ik sil aanst wis wer in ôfspraak meitsje!’ 
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Verder zijn er dan nog Grytsje & Marijke: ik kom nu echt gauw een keer langs hoor in 
jullie ‘nieuwe’ stekkie. Sandra: al sinds ons 12e jaar schrijven we met elkaar. Hoewel 
de p-mail nu behoorlijk is teruggelopen, is er tegenwoordig de e-mail, en ook een 
gezellig face-to-face contact. We zien elkaar vast gauw weer.  
Femke: ik heb je juist leren kennen in de Nijmeegse tijd, via onze basiscursus 
Oncologie. We hebben veel gedeeld, en ik hoop dat we dat nog heel lang zullen 
doen. Lieve meid, bedankt voor alles! 
 
Sinds de tijd dat ik meer verbonden ben aan Utrecht en omgeving zijn er hele leuke 
contacten bijgekomen.  
Lieve Lianne en Lotte, we hebben al veel gezellige momenten gehad, en veel 
gedeeld. Ik drink er eentje op ons, in ieder geval alvast bedankt voor alles! 
Mijn (ex-)collega’s op het RIVM. Bedankt voor jullie belangstelling naar het verloop 
van het proefschrift. Jullie hebben me met raad en daad bijgestaan. Het proefschrift 
is nu dan toch eindelijk klaar! Nu kunnen we nog meer wijnproeven, stadswandelen, 
uit en thuis eten, bioscoopjes pakken, vogelen, parachutespringen, zeilen, 
luchtballon varen, en wat er ook maar meer in ons opkomt.  
 
De liefste mensen van de hele wereld, die me al mijn hele leven in het oog houden, 
die altijd alleen maar het beste voor mij willen, en die altijd in mij zijn blijven geloven 
en van wie ik zoveel houd, dat zijn mijn ouders. Ik hoop dat jullie nog heel lang door 
kunnen blijven varen. En dat ik weer vaker mee zal kunnen varen. Kan ik weer eens 
in februari mijn badpak aantrekken en overboord springen! 
Tante Bettie, en mijn zusjes Geeske en Jolanda, jullie wil ik ook bedanken voor de 
liefde die jullie me geven. Ik wil zeker niet nalaten om mijn schoonmoeder, en 
Annette & Ron & Eline & Vera & Lennard, Corine & Martin & Sam & Lodewijk & 
Jurre, Henk & Angelique & Merel & Tijmen te bedanken voor de hartelijkheid 
waarmee jullie me de afgelopen jaren steeds hebben ontvangen. Ik ben heel blij met 
jullie als schoonfamilie. En Vera, ik geniet nog steeds van je tekening die je hebt 
gemaakt voor de voorkant van dit boekwerk: hij is echt mooi geworden hoor! Heel 
erg hartelijk bedankt! 
 
Tot slot de spreekwoordelijke ‘last but not least’: mijn liefste mannen, Kees Jan en 
Stef. Kees Jan, jij bent mijn grote emotionele steun en rationele toeverlaat. Ik vind 
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het heerlijk om bij je te zijn, en ik ben blij dat ik eindelijk aan een grote wens van je 
kan voldoen: het opruimen van de paperassen in de studeerkamer! Ik hoop, dat we 
nog heel veel gelukkige jaren samen mogen meemaken. Lieverd, je krijgt een hele 
stevige knuffel en een zoen, als dank voor alles wat je voor me betekent. We hebben 
samen een heerlijke zoon op de wereld gezet! Van hem, en wat/wie de toekomst ons 
meer mag bieden, kunnen we vanaf nu nóg meer samen genieten! 
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Connie Brouwer was born on the 29th of March 1971 in Bergum, Friesland. In 
1989, she finished Gymnasium B at the Drachtster Lyceum, Drachten, Friesland. She 
went to study in Groningen, and finished the bachelor’s education ‘Nutrition and 
Dietetics’ at the Hanzehogeschool, in 1994. Subsequently, she went to the 
Wageningen Agricultural University (WAU) to study ‘Human Nutrition’, with a 
toxicologic orientation. She performed three research projects. The first project at the 
department ‘Human Nutrition’ at the WAU, was dedicated to the composition of a 
food table listing the vitamin B12 content of relevant food stuffs. Subsequently, she 
performed a study at the Toxicology department of the WAU concerning the 
usefulness of the ‘proliferating cell nuclear antigen’ method for determination of the 
risk for colon and duodenum carcinoma in rats. Lastly, she went to the Institute of 
Food Safety and Toxicology, The Danish Veterinary and Food Administration, 
Søborg, Denmark, to study flavonoid metabolism in mice. She graduated in 1997.  
In that same year, she started her PhD project at the Laboratory of Pediatrics 
and Neurology of the University Medical Center St Radboud in Nijmegen. The results 
of this project are described in this thesis. Since February 2002, she has been 
working as a preclinical assessor at the Centre for Biological Medicines and Medical 
Technology of the National Institute of Public Health and the Environment, Bilthoven.  
 
